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Abstract 
 
High-risk human papillomaviruses (HR-HPV), typified by HPV16 and HPV18, are the cause of 
several epithelial cancers, including cervical, oropharyngeal, and anogenital carcinomas. The 
mechanisms by which HR-HPV infections lead to malignant cell transformation rely mainly 
on the activities of two viral oncoproteins, E6 and E7, which synergistically act to transform 
and immortalize the infected cell. E6 is considered the main oncoprotein responsible for 
cellular transformation, since its sustained expression and transforming activity are key 
elements for tumor progression. Recent structural and mutational studies revealed the 
importance of a conserved alpha-heliǆ ;αϮͿ iŶ the N-terminal domain of E6 for the 
productive degradation of p53. Indeed, a feǁ keǇ ƌesidues of the αϮ-helix form a 
hydrophobic pocket on E6 protein surface which was shown to be crucially involved in the 
iŶteƌaĐtioŶ ǁith pϱϯ. NotaďlǇ, the αϮ-helix was previously characterized to be important also 
for E6 self-association, an event poorly understood that involves the same amino acids 
iŵpoƌtaŶt foƌ the ďiŶdiŶg to pϱϯ. Thus, the hǇdƌophoďiĐ poĐket ĐoƌƌespoŶdiŶg to the αϮ-
helix of E6 seems to be important for different protein-protein interactions and represents a 
new attractive target for the development of anti-E6 compounds, since no specific anti-HPV 
drugs exist so far.  
In the present PhD thesis we demonstrate that HPV16 E6 can dimerize not only in vitro but 
also iŶ Đells, aŶd the diŵeƌizatioŶ is speĐifiĐallǇ dƌiǀeŶ ďǇ the αϮ-helix. In addition, our 
results suggest that the homodimerization of E6 is not required for the degradation of p53 
and thus these two interactions, i.e., the binding of E6 to p53 and E6 self-association, likely 
occur independently of each other and probably in different cellular compartments. 
Furthermore, we observed that E6 induces the upregulation of TAZ which is, together with 
YAP, the main transducer of the Hippo signaling pathway, controlling organ size, 
tumorigenesis and metastasis. Strikingly, this process seems to require E6 self-association, 
since dimerization-defective E6 mutants are unable to upregulate TAZ in transfected cells. 
Finally, with the goal to develop dual inhibitors that could block the protein-protein 
iŶteƌaĐtioŶs oĐĐuƌƌiŶg oŶ the αϮ-helix of the viral oncoprotein, we performed in silico drug 
screenings, taking advantage of the available structural models, and identified some 
ĐaŶdidate ĐoŵpouŶds fittiŶg oŶ the hǇdƌophoďiĐ Đoƌe of the αϮ-helix of E6. We then 
evaluated their ability to impair both E6 self-association and the E6-mediated degradation of 
p53. Strikingly, we identified one compound able to block both interactions, thus 
representing a candidate dual inhibitor, which could also induce the downregulation of E6 
protein levels in parallel to its ability to rescue p53 in transfected cells. This compound also 
exhibited specific anti-proliferative and anti-clonogenic activities against HPV-positive cells. 
In conclusion, the present study successfully investigated and elucidated the potential role 
of E6 homodimerization with regard to the transforming activities of the viral oncoprotein, 
aŶd deŵoŶstƌated that taƌgetiŶg the αϮ-helix of high-risk E6 proteins may represent a novel 
fascinating strategy for the development of anti-E6 compounds. 
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Riassunto 
 
I papillomavirus umani ad alto rischio (HR-HPV), rappresentati dai genotipi 16 e 18, sono 
Đausa di diǀeƌsi tuŵoƌi epiteliali, iŶĐlusi ĐaƌĐiŶoŵi della ĐeƌǀiĐe uteƌiŶa, dell͛oƌofaƌiŶge e 
anogenitali. I meccanismi attraverso i quali le infezioni da HR-HPV portano alla 
trasformazione cellulare maligna, si basano sulle attività di due oncoproteine virali, E6 ed E7, 
le quali agiscono sinergisticamente per trasformare ed immortalizzare le cellule infettate. E6 
è considerata la principale oncoproteina responsabile della trasformazione cellulare, in 
quanto la sua prolungata espressione ed attività trasformante sono elementi chiave per la 
progressione del tumore. Alcuni recenti studi strutturali e mutazionali hanno rivelato 
l͛iŵpoƌtaŶza di uŶ͛alfa eliĐa ;αϮͿ Ŷel doŵiŶio N-terminale di E6, altamente conservata tra i 
vari genotipi di HR-HPV, per la degradazione di p53. Infatti, è stato visto che alcuni residui 
Đhiaǀe di Ƌuest͛alfa eliĐa foƌŵaŶo uŶa tasĐa idƌofoďiĐa sulla supeƌfiĐie di Eϲ ĐƌuĐiale peƌ 
l͛iŶteƌazioŶe ĐoŶ pϱϯ. IŶ più, eƌa stato ǀisto aŶĐhe Đhe Ƌuest͛alfa eliĐa ŵedia 
l͛autoassoĐiazioŶe di Eϲ, uŶ pƌoĐesso Đhe, seďďeŶe poĐo Đaƌatteƌizzato, ĐoiŶǀolge gli stessi 
aminoacidi necessari per il legame a p53. Perciò, la tasca idrofobica corrispondente all͛eliĐa 
αϮ di Eϲ seŵďƌa esseƌe iŵpoƌtaŶte peƌ diǀeƌse iŶteƌazioŶi pƌoteiŶa-proteina e rappresenta 
un nuovo affascinante target per lo sviluppo di composti anti-E6, considerato che ad oggi 
non esistono ancora farmaci contro HPV.  
In questa tesi di dottorato dimostriamo come E6 di HPV16 possa dimerizzare non solo in 
vitro ma anche nelle cellule, e come la dimerizzazione di E6 sia mediata specificamente 
dall͛eliĐa αϮ. IŶoltƌe, i Ŷostƌi ƌisultati suggeƌisĐoŶo Đhe la diŵeƌizzazioŶe di Eϲ ŶoŶ è 
necessaria per la degradazione di p53 e che quindi queste due interazioni proteina-proteina, 
Đioè il legaŵe di Eϲ a pϱϯ e l͛autoassoĐiazioŶe di Eϲ, possaŶo aǀǀeŶiƌe iŶdipeŶdeŶteŵeŶte 
l͛uŶa dall͛altƌa e pƌoďaďilŵeŶte iŶ ĐoŵpaƌtiŵeŶti Đellulaƌi diǀeƌsi. IŶ aggiuŶta aďďiaŵo 
osservato che E6 stabilizza i livelli di TAZ che, assieme a YAP, è il principale effettore della via 
di segnalazione Hippo, che regola la crescita degli organi ed anche i processi di tumorigenesi 
e di metastasi. Sorprendentemente, questo processo pare richiedeƌe l͛autoassoĐiazioŶe di 
E6, in quanto mutanti di E6 incapaci di dimerizzare, sono incapaci anche di stabilizzare TAZ in 
Đellule tƌasfettate. IŶfiŶe, ĐoŶ l͛oďiettiǀo di sǀiluppaƌe iŶiďitoƌi dupliĐi Đhe possaŶo ďloĐĐaƌe 
entrambe le interazioni proteina-proteiŶa Đhe ĐoiŶǀolgoŶo l͛eliĐa αϮ dell͛oŶĐopƌoteiŶa 
virale, abbiamo condotto degli screening in silico utilizzando i modelli strutturali disponibili in 
letteratura e abbiamo identificato alcuni composti in grado di legarsi al core idrofobico 
dell͛eliĐa αϮ di E6. Abbiamo quindi valutato la loro capacità di interferire sia con 
l͛autoassoĐiazioŶe di Eϲ Đhe ĐoŶ la degƌadazioŶe di pϱϯ iŶdotta da Eϲ. “oƌpƌeŶdeŶteŵeŶte, 
un composto si è rivelato capace di bloccare entrambe le interazioni, rappresentando quindi 
un potenziale inibitore duplice, e ha mostrato anche le capacità di indurre una diminuzione 
dei livelli di E6 in parallelo alla sua abilità di prevenire la degradazione di p53 in cellule 
trasfettate. In più, questo composto ha mostrato anche attività anti-proliferative e anti-
clonogeniche specifiche contro cellule HPV-positive.  
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In conclusione, questo studio ha investigato con successo e chiarito il potenziale ruolo della 
diŵeƌizzazioŶe di Eϲ ƌelatiǀaŵeŶte alle attiǀità tƌasfoƌŵaŶti dell͛oŶĐopƌoteiŶa ǀiƌale, e ha 
diŵostƌato Đhe Đolpiƌe l͛eliĐa αϮ di Eϲ può ƌappƌeseŶtaƌe uŶa stƌategia iŶŶoǀatiǀa peƌ lo 
sviluppo di composti anti-E6. 
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1. Introduction 
 
1.1 Human papillomaviruses. 
 
Human Papillomaviruses (HPVs) belong to the familiy of Papillomaviridae, which includes 
over 300 different papillomaviruses that infect a wide range of mammals and vertebrates. 
These viruses have evolved over millions of years to replicate themselves in epithelial 
tissues, with the ability to infect different anatomical sites, depending on the viral genotype 
involved [Egawa et al., 2015]. 
Papillomaviruses are small, non-enveloped, ichosaedral DNA viruses of about 50-55 nm in 
diameter. In general, viral protein capsid is composed of 72 capsomeres, protecting a circular 
double-stranded DNA (dsDNA) genome of about 8 kilobases. The HPV genome encodes eight 
genes, six early (E1, E2, E4, E5, E6 and E7) and two late genes (L1 and L2), the latter encoding 
the two structural proteins composing the viral capsid (Figure 1.1).  
To date, about 200 different HPV genotypes have been identified and characterized, and 
they are divided into 5 different classes (alpha-, beta-, gamma-, mu-, nu-) depending on 
evolutionary similarities. HPVs generally infect the basal keratinocytes of a differentiated 
epithelium and replicate following cell differentiation through all the epithelial layers 
towards the surface. Depending on the epithelial site of infection, HPVs can replicate both in 
cutaneous and in mucosal tissues, with particular genotype-specificity. However, despite the 
big heterogeneity, viruses belonging to different classes may replicate in the same epithelial 
niche and anatomical site, wherein each viral genotype has evolved to complete its life-cycle. 
HPVs are so common among the population that nearly all humans are believed to have 
been exposed to the virus at least once during their lives [CDC fact sheet]. 
HPVs can cause distinctive epithelial lesions, usually characterized by the hyper-proliferation 
of the infected cells wherein the virus is replicating, but unapparent, asymptomatic or 
malignant lesions can also occur. Nevertheless, most HPV infections are usually cleared by 
the immune system and do not cause visible pathologies.   
12 
 
 
Figure 1.1. Human papillomavirus. (A) Electron microscope image of human 
papillomaviruses (German Cancer Research Center, DKFZ). (B) 3D model of a human 
papillomavirus (HPV) showing the cross section of a HPV virion. All virus-encoded proteins 
are shown in yellow shades and host-cell structures (including nucleosomes and surface 
glycosides) are shown in grey. The way of genome packing is hypothetical. Original image 
created by the Visual Science Company (www.visualsciencecompany.com/hpv). 
 
 
1.2 Taxonomic classification. 
 
According to the Papillomavirus Genome Database (PaVE, https://pave.niaid.nih.gov), 
approximately 220 different HPV genotypes have been classified to date (accessed 
September 2016). HPV classification relies on genomic homology rather than differences in 
the anatomical sites of infection or lesion characteristics. The phylogenetic algorithms used 
to classify new HPV types compare whole genome or subgenomic sequences [De Villiers et 
al., 2004]. Thus, viruses belonging to different classes may replicate in the same epithelial 
compartment and share common clinical characteristics.  
HPVs are divided into 5 different classes, also referred as genera, i.e., Alpha-papillomavirus, 
Beta-papillomavirus, Gamma-papillomavirus, Mu-papillomavirus and Nu-papillomavirus 
(Figure 1.2).   
The major group of HPVs is the Alpha genus. PVs belonging to this group can infect both 
mucosal and cutaneous epithelia. They include the supergroup of sexually transmitted PVs, 
infecting the skin and mucosa of the genital tract, but they can also replicate in oral sites, 
such as pharynx and tongue. Cutaneous Alpha-PVs induce benign lesions while mucosal 
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viruses can also induce malignant neoplasias through a process of cellular transformation. 
Mucosal Alpha-PVs are thus subdivided iŶto ͚loǁ-ƌisk͛ aŶd ͚high-ƌisk͛ geŶotǇpes, depeŶdiŶg 
on their ability to induce cancer [Doorbar et al., 2012].  
Beta-PVs replicate exclusively in the skin. They usually do not induce visible lesions and 
persist in a latent state in general population. However, unapparent or latent infections of 
Beta-PVs can reactivate in immunocompromised patients or in individuals genetically 
susceptible to these viruses. Sporadically, these patients can develop non-melanoma skin 
cancer (NMSC) as a result of Beta-PV infections [Howley and Pfister, 2015].  
Finally, HPV genotypes classified in the Gamma-, Mu- and Nu- genera all replicate in 
cutaneous epithelia. They usually induce benign lesions but they can also persist in a latent 
state. Although not extensively studied as the previous classes, Gamma- and Mu-PV 
infections are usually characterized by distinguishable intracytoplasmic inclusion bodies 
[Bolatti et al., 2016]. In addition, along with Beta-PVs, viruses belonging to the Nu genus are 
also associated to the development of skin cancer [Grimmell et al., 1988]. 
 
 
 
Figure 1.2. Phylogenetic classification of human papillomaviruses based on evolutionary 
similarities. HPVs are divided into 5 different classes: Alpha-, which comprehends low-risk 
cutaneous (light-brown), low-risk mucosal (yellow) and high-risk mucosal (pink) PVs; Beta- 
(blue); Gamma- (green); Mu- (purple); Nu- (orange). High-risk Alphapapillomaviruses 
highlighted iŶ ƌed aƌe ĐoŶfiƌŵed as ͞huŵaŶ ĐaƌĐiŶogeŶs͟, ǁhile the otheƌs aƌe ĐoŶsideƌed 
͞pƌoďaďle͟ oƌ ͞possiďle͟ ĐaƌĐiŶogeŶs [Egaǁa et al., 2015]. 
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1.3 Diseases associated with HPV infections. 
 
HPV infections can induce different types of lesions depending on the epithelial area and 
anatomical site involved, which usually reflect genotype-specificity. Generally, viral life-cycle 
leads to the development of benign skin tumors as a result of cellular uncontrolled 
proliferation, but HPV infection by certain viral genotypes can also induce malignant tumors 
in a subset of anatomical sites [Egawa et al., 2015].  
Cutaneous Alpha-PVs, such as HPV2 and HPV10, replicate in the skin and induce common 
warts (Verruca vulgaris). Common warts are small, rough, usually round-shaped 
excrescences that occur on the skin of hands and feet, but can virtually grow anywhere in 
the body (Figure 1.3A). Sporadically, some cutaneous Alpha-PV, such as HPV7 and HPV3, can 
also replicate in mucosal tissues causing papillomas [Doorbar et al., 2015].  
Mucosal Alpha-PVs, such as HPV32, HPV6, HPV11 and HPV54, replicate in epithelial mucosal 
tissues. They can grow both in the genital or respiratory tract, causing anogenital warts (such 
as condyloma acuminata, venereal warts or anal warts), or oral papillomas, respectively 
(Figure 1.3B-D) [Doorbar et al., 2015]. Although oral papillomas can induce laryngeal 
papillomatosis (a rare, potentially fatal medical condition wherein the uncontrolled growth 
of papillomas can obstruct the airways), lesions caused by these viruses are not considered 
harmful per se, and do not usually correlate with the insurgence of carcinomas, such as anal, 
ĐeƌǀiĐal oƌ oƌophaƌǇŶgeal ĐaŶĐeƌs. Thus, these HPVs aƌe usuallǇ Đlassified as ͚loǁ-risk͛ 
genotypes (LR-HPVs). On the contrary, mucosal Alpha-PVs that strongly correlate with the 
development of epithelial cancers, such as HPV16, HPV18, HPV31, HPV45 and HPV56, are 
Đlassified as ͚high-ƌisk͛ geŶotǇpes ;H‘-HPVs). These viruses replicate in mucosal tissues, 
usually in the genital tract, and are strongly associated with vulvar, anal, penile or cervical 
cancer [Giuliano et al., 2008]. Recently, increasing association between HR-HPV infections 
and the development of head-and-neck squamous cell carcinoma (HNSCC) has also emerged 
[Mallen-St Clair et al., 2016]. At early stages of HR-HPV infection, lesions resemble flat warts 
(discussed below) and are usually classified as intraepithelial neoplasias type 1. If not 
efficiently counteracted by the immune system, these lesions often develop into a more 
severe condition, usually characterized by epigenetic modifications or changes in cell 
signalling, that lead to a dysregulated viral gene expression [Doorbar, 2005]. At this stage, 
lesions are classified as intraepithelial neoplasias type 2 and type 3. These are considered 
precancerous lesions that very easily develop into cancer, where hyper-methylation or 
integration of viral DNA into host genome is observed, with concomitant loss of productive 
viral life-cycle [Dutta et al., 2015].  
Viral genotypes belonging to the Beta genus, such as HPV5, HPV8 and HPV49, replicate 
within cutaneous epithelium and can cause different types of warts, such as common warts, 
plantar warts (Verruca plantaris) and flat warts (Verruca plana). Phenotypically, plantar 
warts are very close to common warts with the unique characteristic to have black tiny dots 
in the center and usually occur on the sole of the feet. Flat warts instead are small, red-
coloured, smooth papillomas that tend to accumulate in large numbers on the face, neck, 
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hands and wrists (Figure 1.3E-F). Infections driven by Beta-PVs tend to remain silent and 
inapparent, with visible manifestations occurring during condition of stress and reduction of 
the immune response. Rarely, Beta-PVs can also induce skin cancers acting synergistically 
with UV radiation and immune suppression to transform keratinocytes [Quint et al., 2015]. 
In addition, Beta-PV infections correlate with Epidermodysplasia verruciformis (also known 
as the tree man illness), a rare genetic disorder in which patients are highly susceptible to 
HPV infections, with high risk of developing skin carcinomas. 
 
Gamma-PVs, Mu-PVs and Nu-PVs, such as HPV4, HPV1 and HPV41, respectively, induce 
benign lesions of the skin, usually common warts or plantar warts. They rarely replicate in 
mucosal tissues and, apart from HPV41, they have been never linked to the development of 
skin cancers.  
 
Figure 1.3. Lesions caused by HPV infections. (A) Common wart occurring on a hand. (B) 
Condyloma acuminata on the perineum. (C) Genital wart occurring in the vaginal introitus. 
(D) Oral squamous papilloma. (E) Plantar wart. (F) Flat warts occurring on the face. 
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1.4 HPV life-cycle. 
 
The molecular mechanisms of HPV life-cycle and the viral genome and protein characteristics 
known to date usually refer to Alpha-PVs. Alpha genus is the main class of HPVs that has 
been extensively studied during the last 30 years and thus most knowledge about HPVs 
derives from some representative genotypes of this class, but general characteristics apply 
to most, if not all, HPVs.   
Papillomaviruses are very simple DNA viruses that encode a restricted small number of viral 
proteins, and thus, their life-cycle is strictly connected to the transcriptional and 
replicational machinery of the infected host cell. Indeed, after centuries of evolution, 
Papillomaviruses have evolved the ability to finely hijack the cellular environment, in order 
to efficiently replicate within the infected cell [Hebner and Laimins, 2006].  
It is commonly accepted that Papillomaviruses require a break in the epithelium to 
successfully infect the host, such as microwounds or abrasions, in order to reach the basal 
keratinocytes of the skin (Figure 1.4). These are S-phase-competent cells which express the 
appropriate cellular machinery required for the initiation of viral replication [Doorbar, 2005]. 
In addition, these cells express the primary and secondary receptors required for viral 
attachment and entry, which occur through the interaction with heparin sulphate 
proteoglycans and alpha-6 integrin, although the involvement of this membrane-associated 
secondary receptor remains somehow controversial [Giroglou et al., 2001; Yoon et al., 
2001].  
 
 
Figure 1.4. Schematic representation of the life-cycle of an Alpha-PV (such as HPV2, HPV11 
or HPV16) during a productive infection. The patterns of viral gene expression represented 
on the right correspond to the different stages of the viral life-cycle as the infected cell 
migrates towards the epithelial surface [Doorbar, 2005].  
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Once attached, virions are internalized by endocytosis and undergo endosomal transport 
and uncoating [Hindmarsh et al., 2007]. After release from the endosome, viral DNA is 
carried into the nucleus of the cell by L2 protein-DNA complexes [Holmgren et al., 2005]. 
At the early steps of infection, when the viral DNA enters the nucleus of a basal keratinocyte, 
viral proteins E1 and E2 are expressed and viral genome is replicated and maintained as a 
low copy number episome (20-200 copies per cell) [Lambert, 1991]. As soon as the infected 
cell enters mitosis, two daughter cells will be produced both harbouring episomal viral DNA. 
This process is a consequence of E1 and E2 protein activities, which allow the virus to 
synchronally replicate along with the cellular genome and subsequently segregate its DNA by 
tethering the viral episomes to cellular chromatin [Oliveira et al., 2006]. It has been 
suggested that persistance of HPV requires the infection of a basal stem cell, rather than a 
transiently amplifying suprabasal cell [Egawa, 2003]. Thus, as the basal stem cell divides, a 
differentiating daughter cell will be produced, migrating outwards through the suprabasal 
layers, while the other will not differentiate, allowing the persistance of viral DNA in the 
lower lamina of the epithelium.  
The fate of a normal cell within stratified squamous epithelia is to leave the basal layers and 
proceed towards the surface, generating new mature keratinocytes. This event is 
accompanied by a process of terminal differentiation, and thus the differentiating cell leaves 
the cell cycle and stops replicating its own DNA. However, HPV requires an active 
replicational cellular machinery in order to amplify its genome, which will be packed into the 
capsid of the progeny virions in the upper lamina of the epithelium. Infected keratinocytes 
that leave the basal layer do not exit the cell cycle as HPV expresses two oncoproteins, E6 
and E7, whose function is to keep the infected cell in an S phase-like state. These two 
proteins modulate the regulation of the cell cycle by impairing the negative regulatory 
signals that would stop cellular growth. E6 and E7 act on many different cellular proteins 
important for cell-cycle control, differentiation and apoptosis, for example p53 and pRb, 
respectively [Howley, 2006]. Thus, the infected cell continuously proliferates while migrating 
within the parabasal and middle layers, allowing HPV to successfully amplify its DNA.  
At this stage of infection, the expression pattern of viral proteins changes and HPV enhances 
the expression of E1 and E2 and, together with E6 and E7, it starts expressing also E4 and E5. 
These two proteins modify the cellular environment contributing to viral genome 
amplification [Davy et al., 2009]. E5 is the third minor oncoprotein, whose function is to 
contribute to cellular proliferation by cooperating with E6 and E7 [Bouvard et al., 1994]. E4 is 
highly expressed in the middle-upper layers and blocks the infected cell in the G2 to M phase 
transition, creating the optimal environment for viral DNA amplification [Davy et al., 2005]. 
 As the infected cell reaches the granular layer of the epithelium, it exits the cell-cycle, and 
the virus starts expressing L1 and L2 viral proteins while retaining only high expression levels 
of E4. L1 and L2 are the major and minor coating proteins of the capsid, respectively, and 
allow viral genome encapsidation inside the nucleus of the infected cell [Barksdale and 
Baker, 1993]. L2 binds on the viral genome and induce genome packaging inside L1-rich 
icosahedral capsid particles. Finally, virus maturation occurs in the most superificial layers, 
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wherein abundant disulphide bonds occur between L1 molecules, creating highly stable 
virions. In addition, high levels of E4, organized into amyloid fibres, disrupt keratin structure, 
contributing to viral release and transmission [McIntosh et al., 2008].  
Progeny virions are thus released from the superficial dying keratinocytes and spread in the 
surrounding tissue. 
 
 
1.4.1 Genome architecture. 
 
With regard to viral genome architecture, HPVs possess a double-stranded DNA genome that 
does not usually integrate and exists in the form of episome, with an average length of about 
8kb. HPV genome is divided into 3 functional regions: one non-coding regulatory region 
named Long Control Region (LCR) and two groups of Open Reading Frames (ORF), named 
early (E) and late (L), respectively. 
The LCR contains transcription factor-binding sites and the origin of replication, along with 
enhancers and silencers. Both viral and cellular proteins can bind on the LCR. E1 and E2 
regulate the replication of viral DNA and transcription of early proteins, respectively, and 
possess highly conserved binding sites on viral LCR [Desaintes and Demeret, 1996]. Cellular 
transcription factors such as Nuclear Factor 1 (NF1), Activator Protein 1 (AP1) and Specificity 
protein 1 (Sp1) can also bind, promoting the transcription of viral proteins at the early stage 
of infection [Chong et al., 1991]. 
The early ORF includes genes encoding all the early viral proteins (E1, E2, E4, E5, E6 and E7) 
and occupies most of the viral genome. Transcription of the early proteins occurs through 
multiple early promoters and stops at different early polyadenilation sites (PE and pAE, 
respectively), producing polycistronic mRNAs [Zheng and Baker, 2006]. In addition, viral 
mRNAs undergo abundant alternative splicing events, thus increasing the extent of 
translated proteins [Rush et al., 2005]. 
The third region of viral genome is the late ORF which encodes the two structural proteins, 
L1 and L2. Although the late ORF is located downstream of the early ORF, late promoters 
(PL) are situated within the early ORF and thus some early proteins are still transcribed 
during the late phase of infection, such as E5 and E4 [Ozbun and Meyers, 1997]. The 
activation of PLs follows cell differentiation in the upper epithelial layers [Geisen and Kahn, 
1996]. Therefore, viral transcription programs are finely regulated according to the 
differentiation state of the infected cell, involving host transcription factors that are 
differentially expressed from the basal layers towards the surface. 
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1.4.2 E1. 
 
E1 is a replicative protein of about 68 kDa, essential for the replication of viral DNA [Ustav 
and Stenlund, 1991]. It is the only enzyme encoded by HPV. E1 possesses ATPase and DNA 
helicase activities, and belongs to the family of ATPases [Yang et al., 1993]. It is composed of 
three domains: an N-terminal regulatory region, a central DNA-binding domain, and a C-
terminal ATPase/helicase domain that can also mediate E1 oligomerization. The C-terminal 
domain of E1 is the core of its activity, essential to drive viral DNA replication [Amin et al., 
2000]. 
E1 binds with E2, and this interaction facilitates the attachment of E1 to the HPV genome 
[Frattini and Laimins, 1994]. E1 then binds DNA in the dimeric form on specific E1 binding 
sites [Auster and Joshua-Tor, 2004]. Following the denaturation of the origin of replication, 
E1 forms hexamers and this oligomerization is triggered by the interaction of E1 with some 
cellular chaperone proteins [Liu et al., 1998; Enemark and Joshua-Tor, 2006]. These cellular 
factors increase E1 affinity for viral DNA and enhance E1 helicase activity, thus facilitating 
the formation of pre-replication complexes. Once E1 oligomers are formed, the viral protein 
hydrolyses ATP into ADP and the energy is used to unwind the double helix of viral DNA, 
which in turns allows the transcription of viral genes [Sanders and Stenlund, 1998].  
 
In order to carry out the complete replication of viral DNA, E1 recruits several cellular 
proteins involved in eukaryotic genome replication, such as DNA polymerases, 
topoisomerases and replication factors [Melendy et al., 1995]. E1 possesses nuclear 
localization and nuclear export sequences (NLS and NES, respectively), but the role of 
cytoplasmic E1 remains elusive [Fradet-Turcotte et al., 2010]. It can be phosphorylated by 
cyclin/Cdk complexes, and the interaction with these complexes is driven by a cyclin-binding 
motif (CBM) in the N-terminal domain of E1 [Ma et al., 1999]. In addition, it was also shown 
that E1 binds to cellular chromatin and chromatin-remodeling complexes, thus altering the 
structure of nucleosomes in the proximity of viral DNA [Swindle and Engler, 1998]. This was 
suggested to serve as a mechanism to enhance the replication of viral genome and to allow 
viral genes to be efficiently transcribed by the cellular transcriptional machinery. 
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1.4.3 E2. 
 
The viral regulatory protein E2 is a 40 kDa protein composed of 3 functional regions: an N-
terminal transactivating domain, typical of transcription factors, a central hinge region and a 
C-terminal DNA binding/dimerization domain.  
E2 works as a transcription factor during the viral life-cycle and fulfills its functions mainly in 
the form of dimers [Hedge et al., 1992]. The main function of E2 is to regulate the 
transcription of viral genes by binding on different E2-binding sites on the LCR [McBride et 
al., 1991]. Viral gene transcription relies on active cellular transcriptional machinery, and 
indeed, a complex framework of interactions between E2 and different cellular transcription 
factors, including p300 and AP1, exists [Krüppel et al., 2008]. E2 is thought to regulate the 
transcription in a dose-dependent manner, in such a way that at low concentrations it drives 
the transcription of early genes, while at higher concentrations the transcription is impaired, 
possibly by hindering the recruitment of cellular transcription factors on viral promoters 
[Steger and Corbach, 1997]. Additionally, E2 can regulate the transcription of different 
cellular genes, thus altering their expression depending on the phase of the HPV life-cycle 
[Lee et al., 2002]. 
Apart from its crucial role in gene transcription, E2 is also important for the regulation of 
viral DNA replication and genome partitioning [Sarafi and McBride, 1995]. Indeed, through 
its N-terminal domain, E2 interacts with the helicase domain of E1 and this interaction 
seƌǀes as aŶ ͞igŶitioŶ sǁitĐh͟ foƌ ǀiƌal DNA ƌepliĐatioŶ. Afteƌ the asseŵďlǇ of Eϭ-E2 dimers, 
E1 can efficiently recognize the origin of replication and E2 is subsequently displaced. In 
addition, E2 interacts with cellular replication factors that are recruited at the origin of 
replication.  
When an infected basal keratinocyte enters mitosis, E2 can ensure the partitioning of viral 
episomes to the daughter cells. This is possible through a direct binding between E2 (bound 
to viral DNA) and mitotic chromosomes, either by binding to chromatin or chromatin-
associated proteins, such as Brd4 or ChLR1 [Baxter et al., 2005]. 
Finally, E2 has also an indirect role for HPV-induced cellular transformation. Indeed, E2 finely 
regulates the expression of E6 and E7 during the viral life-cycle, but loss of E2, along with a 
non-productive viral replication, is a common characteristic of HPV-induced carcinomas 
[Burd, 2003]. This event is usually a result of viral DNA integration into the host genome, an 
accidental process that results in the disruption of the coding sequence (Cds) of E2, thus 
abolishing the production of the protein. As a direct consequence, deregulation of E6 and E7 
genes induces their overexpression, a crucial event for cancer development and progression. 
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1.4.4 E4. 
 
E4 is an early protein that, during the viral life-cycle, accumulates at high levels within the 
middle layers of the epithelium. E4 is expressed from a spliced transcript that starts at the E1 
ORF, and thus the protein is sometimes referred as E1^E4 [Nasseri et al., 1987]. E4 supports 
virus maturation and egress in the middle-upper layers of the epithelium. Although the 
precise molecular mechanisms of this protein remain partly unknown, E4 plays an important 
role in HPV genome amplification in the upper layers by inhibiting mitotic progression and 
cellular replication [Knight et al., 2004]. Infected cells harbouring high levels of E4 are thus 
blocked in the G2 to M phase transition and this event seems to be required for the final 
stage of viral DNA amplification, before genome encapsidation [Davy et al., 2005]. In the 
most superficial layers, where progeny virions are produced, E4 is crucial for viral release as 
it assembles into amyloid fibres that disrupt cell architecture [McIntosh et al., 2008]. 
 
 
1.4.5 E5. 
 
E5 is a very small, highly hydrophobic protein of about 80 amino acids. It is an accessory 
protein whose physiologic role is to cooperate with E6 and E7 for efficient hijacking of 
cellular environment [Moody and Laimins, 2010]. Consequently, like E6 and E7, E5 is 
considered an oncoprotein for its ability to interfere with some carcinogenic signaling 
pathways. Due to its extreme hydrophobicity, E5 is hardly detectable and is generally 
expressed at low levels [Disbrow et al., 2003]. E5 localizes within cellular membranes, 
particularly within the endoplasmic reticulum (ER), plasma or nuclear membranes, 
depending on the viral genotype [Conrad et al., 1993]. For example, high-risk E5 proteins 
preferentially localize within the ER membranes. The main function of E5 is to prevent cell 
death by inhibiting extrinsic death receptor-mediated and intrinsic ER stress-induced 
apoptosis [Jiang and Yue, 2013]. E5 can impair the accumulation of Fas receptors and the 
formation of DISC, induced by TRAIL, on the plasma membrane. Due to its ability to localize 
within the ER, E5 suppresses also the expression of different cellular proteins of the ER stress 
pathway, such as IRE1α. This aĐtiǀitǇ pƌeǀeŶts pƌo-apoptotic signals that can activate cell 
death through intrinsic apoptosis. Although classified as an oncoprotein, E5 is rarely 
detected in cervical cancers as viral DNA integration results in loss of E5 protein expression 
[Chang et al., 2001]. For this reason, and also for being the smallest virus-encoded 
oncoprotein, researchers usually refer to E5 as the third minor HPV oncoprotein. 
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1.4.6 E6. 
 
E6 is a small, cysteine-rich protein of about 150 amino acids. It is an accessory protein 
essential for cellular hijacking in order to promote viral replication [Howie et al., 2009]. For 
its crucial activity and carcinogenic potential, E6 is considered the main HPV oncogene. 
Structurally, E6 is composed of just two zinc-like finger domains (named E6N and E6C, 
respectively), which both contain two highly conserved cysteine motifs (CxxC), connected by 
a flexible loop of about 35 amino acids. In addition, high-risk E6 proteins possess a C-
terminal class I unstructured PDZ-binding motif (PBM) that confers the ability to bind cellular 
PDZ-containing proteins, such as Scribble (hScrib) and Disc Large (hDlg) (Figure 1.5).  
 
Figure 1.5. Structural model of HPV16 E6 with the LxxLL helical motif of E6AP tightening the 
conformation of the viral oncoprotein (PDB accession code: 4GIZ). Cartoon representation 
on the right includes the PBM (PDB accession code: 2KPL). The model was generated in 
PyMol (DeLano Scientific, California, USA). 
 
The physiological role of E6 is to keep the infected cell in an S-phase-like state, cooperating 
with E7 for efficient cellular hijacking [Hebner and Laimins, 2006]. In general, E6 is known to 
block p53-mediated pathways, preventing cellular apoptosis and growth arrest that would 
result as a consequence of E7 activity [Werness et al., 1990; Kessis et al., 1993]. Although 
there are differences between the activities of low-risk and high-risk variants, all E6 proteins 
possess no enzymatic activity and trigger their functions only through protein-protein 
interactions.  
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In general, E6 has evolved the ability to bind several cellular proteins and induce their 
degradation, taking advantage of the cellular proteasome machinery [Scheffner et al., 1990]. 
High-risk E6 proteins can induce the degradation of its targets by binding to cellular ubiquitin 
ligases, such as Ubiquitin-protein ligase E3A, also known as E6-associated protein (E6AP) 
[Huibregtse et al., 1993]. Once bound to E6AP, E6 binds to its cellular targets and stimulates 
their polyubiquitination. In addition to p53, many other cellular proteins are degraded in a 
similar manner, such as procaspase 8, Bak, Scribble and MAGI-1 (see also Paragraph 1.6.1) 
[Thomas and Banks, 1998; Nakagawa and Huibregtse, 2000; Glaunsinger et al., 2000; 
Filippova et al., 2007].  
E6 is a very unstable protein that easily aggregates and precipitates in vitro with a high 
cellular turnover [Kehmeier et al., 2002; Zanier et al., 2007; Zanier et al., 2010]. Within the 
infected cell, E6 is generally located within the nucleus, and its nuclear import is mediated by 
its NLSs, but different localizations have been reported depending on the viral genotype 
involved [Tao et al., 2003; Mesplède et al., 2012].  
E6 is translated from a bicistronic pre-mRNA that comprehends coding sequences of both E6 
and E7 [Schwartz, 2013]. In addition, high-risk E6 proteins undergoe alternative splicing 
events, which produce a subset of different mRNAs that encode smaller spliced variants, 
such as E6*I and E6*II [Cornelissen et al., 1990]. These are the two main spliced isoforms 
whose roles remain so far elusive. Anyway, with regard to E6 oncogenic activities, several 
reports pointed to a negative regulatory function of E6*I, which seems to modulate the 
activity of the full-length protein by direct binding [Pim et al., 1997; Pim and Banks, 1999]. 
However, other reports have reported an intrinsic oncogenic potential of E6*I, which can 
induce the degradation of different tumor-suppressor proteins in the absence of full-length 
E6 [Pim et al., 2009]. The expression levels of both spliced isoforms vary depending on the 
viral genotype, but E6*I is usually expressed at levels comparable to those of the full-length 
protein, and thus it might substantially contribute to the E6-mediated mechanisms of 
cellular transformation. 
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1.4.7 E7. 
 
E7 is an acidic protein of about 100 amino acids which mainly localizes in the nucleus of 
infected cells [Knapp et al., 2011]. It is composed of 3 conserved regions (CR1, CR2 and CR3, 
respectively), the first two included within the N-terminal domain, the third in the C-terminal 
domain. The N-terminus of E7 (CR1/CR2) is unstructured and might fold only upon 
interactions with cellular targets, while the C-terminal domain is tightly packed into a zinc 
finger domain.  
The main biological function of E7 is to induce cellular proliferation by impairing the exit 
from the cell cycle, thus inducing cellular immortalization [Hebner and Laimins, 2006]. This is 
a necessary step to promote viral replication, as it keeps the infected cell in S-phase, thus 
enhancing the replication of viral DNA. Similarly to other viral oncoproteins, with which it 
shares sequence similarity (such as polyomavirus early T-antigens), E7 can block the growth 
arrest of infected cells by impairing the activities of cellular retinoblastoma (Rb) proteins 
[Münger et al., 1989]. E7 of both low-risk and high-risk PVs can bind pRb and pRb-related 
proteins, such as p107 and p130, with differential affinities depending on the viral genotype 
[Hu et al., 1995]. Either pRb degradation or pRb phosphorylation have been reported 
[McIntyre et al., 1996; Huh et al., 2007]. In any case, E7 binds to pRb through a highly 
conserved LxCxE motif in its N-terminal domain. The interaction induces pRb inactivation or 
its proteasome-dependent degradation, and the N-terminal domain of E7 represents the 
core of its activity [Lee et al., 1998]. However, due to its unfoldedness, structural studies on 
the N-terminal domain of E7 have been so far hampered [Garcia-Alai et al., 2007(a)]. 
Similarly to E6, E7 can also interact with many other cellular proteins, such as p21, p600 and 
c-Myc (see also Paragraph 1.6.1) [Huh et al., 2005; Wang et al., 2007; Shin et al., 2009]. The 
compact structure of the C-terminal domain of E7 allowed structural studies both through 
NMR or crystallization [Ohlenschlager et al., 2006; Liu et al., 2006]. This region seems to 
serve as a platform for different protein interactions as well as for E7 dimerization, whose 
role seems to be anyhow unrelated to the immortalization activity of the viral protein. 
As mentioned in Paragraph 1.4.6, E7 is translated from a bicistronic pre-mRNA that 
undergoes multiple splicing events. Generally, E7 is translated from a spliced mRNA that also 
encodes for E6*I [Schwartz, 2013]. Very recently, a spliced E6^E7 isoform has been also 
reported [Ajiro and Zheng, 2015].  
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1.4.8 L1 and L2. 
 
L1 and L2 are structural proteins that compose the viral capsid, with an average diameter of 
55 nm. The viral capsid has an icosahedral symmetry and is composed of 72 pentamers. A 
single pentameric unit contains 5 copies of L1, and thus, a total of 360 molecules form the 
virion. 
Due to its preponderance in the structure of viral capsid, L1 is considered the major coating 
protein. It is highly conserved among PVs and mediates also viral attachment by binding to 
cell surface receptors of basal keratinocytes. Viral entry is a complex process that involves 
different protein-protein interactions and relies also on the activity of L2, which is exposed 
to the surface of the virion upon viral attachment [Sapp and Day, 2009].  
L2 is considered the minor coating protein and localizes internally into the virion, since it 
cannot be detected on the external surface [Richards et al., 2006]. When exposed, it binds to 
a secondary receptor on the cellular membrane, mediating the entry of the L2-genome 
complex. Inside the cell, L2 drives the transport of viral genome into the nucleus by binding 
to syntaxin18 and through its NLS [Bossis et al., 2005]. In addition, L2 is important for 
genome packaging as it binds to L1 through hydrophobic interactions. The stoichiometry of 
L1-L2 complexes is 5:1, and thus, one molecule of L2 can bind a single pentameric unit 
[Finnen et al., 2003]. 
26 
 
1.5 Epidemiology and current therapies. 
 
The incidence of HPV infections is so high among general population that approximately all 
humans are believed to have been infected by a HPV genotype, belonging to any of the five 
genera, at least once during their lives. This is due to the ubiquitous presence of the virus 
worldwide, making it one of the most common viral infectious agent, together with 
herpesviruses and rhinoviruses. However, accurate estimates are practically impossible 
because most of HPV infections are efficiently cleared by the immune system, usually within 
18 months from the initial infection, and cause unapparent or asymptomatic infection 
diseases [Stanley, 2008]. 
Classification of HPVs is based on the ability of a viral genotype to induce malignant lesions, 
and thus reflects the subdivision into low-risk and high-risk genotypes. Epidemiologically, the 
incidence of HPV infections every year usually refers to the prevalence of mucosal Alpha-PVs 
among the population suffering from epithelial neoplasias, usually in the anogenital area 
[Munoz et al., 2003]. Indeed, HPV is the most common sexually transmitted infectious agent, 
which can infect both males and females, particularly among young persons within the first 
years after sexual debut [Dunne et al., 2007]. The prevalence of HPV infections in the genital 
area is about 70 million cases only in the United States of America, with an incidence of 14 
new million cases every year. Anyhow, the presence of Alpha-PVs is not solely restricted to 
the genital area, since HPVs can also replicate in the oropharyngeal tract, and thus the 
prevalence of HPV infections might be globally underestimated. 
In general, the estimated lifetime risk of a HPV infection is very high, but only about 1% of all 
infections will develop cancer. This process requires the persistence of HPV and the inability 
of the host immune system to completely remove the infected cells over a prolonged period 
of time [Siegel et al., 2014]. HPV infections correlate with the development of different 
mucosal malignancies. They are the aetiological agents of about 99% cases of cervical 
cancer, 90% cases of cancer of the anus, approximately 70% cases of vaginal and penile 
cancers and a variable percentage of oropharyngeal cancers (between 30% and 60%) [CDC, 
Centers for Disease Control and Prevention]. Cervical cancer is the 7th most common type of 
malignant neoplasia worldwide, and with approximately 500,000 new cases every year, it is 
the 4th most common cancer in women, with an extremely high mortality rate (50%) [WCRF 
International]. However, oropharyngeal cancer incidence is expected to surpass cervical 
cancer by 2020 [Garland et al., 2016]. 
To date, no specific anti-HPV drugs are commercially available in order to fight pre-existing 
infections. Prophylactic vaccination has been employed since 2006 as a first line strategy 
against HPV infections and the spreading of HPV-induced malignancies. Back in 1992, Merck 
Inc. initiated the HPV Vaccine program. After extensive research on the production of stable 
and immunogenic virus-like paƌtiĐles ;VLPͿ, iŶ the eaƌlǇ ϮϬϬϬ͛s Phase II/III ĐliŶical trials 
started using stable L1-based VLPs produced in yeast, as the L1 protein was known to be 
highly immunogenic. In 2006, the quadrivalent (4vHPV) Gardasil® was licensed by the Food 
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and Drug Administration (FDA), protecting from genotypes 16, 18, 6 and 11 females between 
9 and 26 years old [Villa et al., 2005]. Subsequently, the bivalent (2vHPV) Cervarix® was 
developed by GlaxoSmithKline and licensed by the FDA, protecting from genotypes 16 and 
18. In the years after, the license was extended also for males and in 2014, the nonavalent 
vaccine (9vHPV) was further developed and licensed for protecting both males and females 
against genotypes 16, 18, 6, 11, 31, 33, 45, 52 and 58 [Bryan et al., 2016]. Anti-HPV vaccines 
have been developed in order to limit the spreading of genital warts (mainly caused by HPV6 
and 11) and anogenital cancers (induced by the most common high-risk genotypes, i.e., 
HPV16, 18, 31, 33, 45, 52, and 58). Indeed, data emerging in the last years support the 
effectiveness of the vaccination program, as the incidence of HPV6, 11, 16 and 18 decreased 
from 12% to 5% in 2013 in the USA among females 14-19 years old [Markowitz et al., 2013]. 
In addition, a decline of cervical high-grade lesions prevalence was also observed in Australia 
in 2011 [Immunize Australian Program]. However, prophylactic vaccines have no effect 
against pre-existing infections and thus the real effectiveness in the general population is so 
far limited, as the herd immunity will be effective only after a prolonged period of time and 
with a sustained worldwide vaccination campaign. 
In the absence of specific anti-HPV drugs, current therapies involve the use of classic 
treatments, such as surgery, radiotherapy and chemotherapy (alone or in combination). 
Conization is one of the common surgery treatments, which is a clinical procedure consisting 
iŶ the ƌeŵoǀal of a ͞suspeĐted͟ ĐoŶiĐ pieĐe of tissue fƌoŵ the Đeƌǀiǆ. Hoǁeǀeƌ, ǁheŶ the 
development of a malignant lesion is evident, total hysterectomy is usually employed, which 
consists in the removal of the uterus. In the most severe cases of invasive carcinomas, 
radical trachelectomy or pelvic exenteration are employed, with the removal of the uterus 
and surrounding tissues.  
Radiotherapy is a treatment that exploits high-energy wavelengths to kill cancer cells, but 
with severe collateral effects, since also healthy cells surrounding the tumour are affected. 
Chemotherapy treatments exploit chemical substances that hamper tumour growth before 
surgical intervention. The treatment can be systemic or localized, but in both cases collateral 
effects are often present. 
Current drug therapies rely on the use of different drugs proved to be efficacious in the 
treatment of HPV-induced benign and malignant hyperproliferations. Cidofovir (CDV) is an 
acyclic nucleoside phosphonate known for its broad-spectrum antiviral activity against DNA 
viruses, proved to be efficacious in patients suffering from HPV-associated diseases, showing 
antiproliferative properties [Mertens et al., 2016]. Other drugs used to treat HPV-induced 
diseases are Imiquimod and Cisplatin [Busch et al., 2016]. However, all these drugs have 
demonstrated insufficient efficacy if used alone, and Cisplatin, which is a drug commonly 
used for cancer chemotherapy, has demonstrated high renal cytotoxic effects with only 10-
20% of responses. [Suarez-Ibarrola et al., 2016]. In addition, the use of chemotherapeutic 
agents can result in drug resistance caused by the upregulation of certain signalling 
pathways in cancer cells. 
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1.6 Virus-induced human oncogenesis. 
 
The mechanisms of human viral oncogenesis are generally characterized by their intimate 
addiction to the activity of one or more viral oncoproteins. Oncoviruses are a heterogeneous 
class of both DNA and RNA viruses that possess the unique ability to transform and 
immortalize the infected cell through the expression of distinct oncogenes [Mesri et al., 
2014]. The role of these viral oncoproteins is strictly connected to the success of viral 
replication and they generally serve as a ͞Đellulaƌ sǁitĐh͟, keepiŶg the iŶfeĐted Đell oŶ a 
competent state for productive viral replication (Figure 1.6). Furthermore, centuries of 
evolutionary pressure have selected viral genotypes able to maximize viral replication and 
escape the immune system in the infected tissue. This process has in turn selected the most 
effiĐieŶt ǀiƌal pƌoteiŶ ǀaƌiaŶts that ĐaŶ poteŶtiallǇ iŶduĐe ĐaŶĐeƌ, a ͞side effeĐt͟ of the 
natural role of these proteins. 
As a general rule, the continuous activity of the viral oncoprotein(s), usually associated with 
persistent infection, is a necessary, but not sufficient, trait for cancer development. The 
ŵultistep pƌoĐess of ǀiƌal oŶĐogeŶesis ƌelies oŶ the iŶtiŵate Ŷeed of aŶ ͞eŶǀiƌoŶŵeŶtal Đo-
faĐtoƌ͟, ǁhiĐh ĐaŶ ďe eitheƌ a ĐhƌoŶiĐ iŶflammatory response or a condition of 
immunosuppression, which drives the infected cell through a slow process of malignant 
transformation. Viral oncoproteins generally target some selected cellular pathways, which 
are the central regulators of cell cycle, cell survival and cellular proliferation, in particular 
p53, NF-kB, Wnt, hTERT, Hippo and pRb-mediated pathways. 
 
 
Figure 1.6. General mechanisms of virus-induced oncogenesis. Cancer hallmarks depicted 
on the right result as a consequence of the activities of the viral oncoproteins, which are 
needed to maximize viral replication and persistence [Mesri et al., 2014].    
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1.6.1 Mechanisms of HPV-induced carcinogenesis. 
 
The mechanisms of HPV-induced carcinogenesis rely on the cooperative and continuous 
activity of E6 and E7. When overexpressed, these two proteins deeply perturb the cellular 
environment, creating the favourable conditions for cellular transformation. As mentioned in 
Paragraph 1.4.6 and 1.4.7, the physiological role of these two proteins is to keep the infected 
cell on a competent state to promote viral replication.  
When a HR-HPV genotype (such as HPV16 or HPV18) infects basal keratinocytes, the virus 
starts replicating within the mucosal epithelium and usually produces a benign lesion (which 
resembles a flat wart) classified as Low-grade Squamous Intraepithelial Lesion (LSIL) or 
intraepithelial neoplasia type 1. Generally, also HR-HPV infections are efficiently cleared by 
the immune system, and thus most infections spontaneously resolve within months. 
However, if the infection persists, lesions caused by HR-HPVs can easily progress towards 
malignancy and develop cancer. This process is a direct consequence of viral DNA integration 
or, alternatively, its hypermethylation, which frequently occur when the infection is driven 
by a high-risk genotype. This event causes the deregulation of viral genes expression, 
resulting in the overexpression of E6 and E7, which are the driving forces for cancer 
development and progression.  
However, evidences suggest that the majority of HR-HPV-associated cancers arise from the 
cervical and anal transformation zones and from the crypts of the oropharynx. In these 
particular epithelial compartments, cells respond differently to the growth signals from the 
neighbouring cells and poorly support viral replication [Egawa et al., 2015]. Thus, viral gene 
expression is poorly controlled and easily results in the development of carcinomas (Figure 
1.7). 
Accordingly, HPV-induced carcinomas have two distinctive characteristics: the loss of 
productive viral life-cycle and the complete addiction of malignant cells to the activity of E6 
and E7. Indeed, viral DNA persists within the transformed keratinocytes, but its integration 
in the host genome ultimately leads to the complete inability to produce progeny virions. 
This event is a result of the progressive loss of all viral proteins, apart from E6 and E7, which 
are preserved and continuously expressed. Thus, at this stage of the infection, viral load 
starts decreasing as the virus irreversibly enters a non-productive life-cycle, and the infected 
cells accumulate higher intracellular levels of E6 and E7 [Doorbar et al., 2012].  
The epithelial lesion progressively develops from a Low-grade to a High-grade Squamous 
Intraepithelial Lesion (HSIL) and secondary genetic changes can accumulate in the host 
genome (corresponding to intraepithelial neoplasias type 2 and 3). However, the slow 
process of cancer development is intimately linked to the continuous activity of the viral 
oncoproteins, since they induce the degradation of several cellular proteins crucial for 
immune response-related pathways, cell-cycle control and apoptosis, which would induce 
cell death if rescued [Jiang and Yue, 2013].  
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In addition, a complex interplay between the two oncoproteins is crucial for cellular 
transformation because they target different cellular pathways, and thus they depend on 
each other in order to create the proper environment for cancer development [Chen, 2015; 
Groves and Coleman, 2015]. 
 
 
Figure 1.7. Model of how HR-HPV infections progress towards malignancy. (A) Schematic 
representation of how a productive HR-HPV infection takes place in a stratified epithelium, 
which requires a microwound in the skin, resulting in the progressive development of a 
carcinoma. (B) Model of how HR-HPV infections at the squamocolumnar junction in the 
transformation zone result in cancer development. This is considered the preferential site 
wherein HR-HPV infections easily progress towards cancer, since these cells are not 
permissive for viral replication. Cells containing viral DNA are shown with blue nuclei 
[Banks et al., 2012]. 
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E7 mainly affects the cellular proteins of the retinoblastoma family, particularly, pRb, p107 
and p130, inducing their proteasome-dependent degradation [Hu et al., 1995]. This event 
occurs through the direct interaction between E7 and Rb proteins, and the recruitment of 
cullin 2 ubiquitin ligase in order to drive their degradation [Huh et al., 2007].  
The physiological role of the Rb proteins is to inhibit E2F transcription factors, thus blocking 
the E2F-mediated transcription of cyclins and cyclin-dependent kinases (CDK). When pRb, 
p107 and p130 are degraded by E7, E2F1-3 can actively transcribe their target genes 
inducing cellular proliferation (Figure 1.8). However, E7-mediated deregulation of the cell 
cycle involves different mechanisms, as E7 can also directly bind and stabilize cyclin/CDK 
complexes, neutralize the activity of CDK inhibitors, such as p21 and p27, and block the 
activity of E2F6 transcription repressor [McIntyre et al., 1996; Huh et al., 2005; McLaughlin-
Drubin et al., 2008; Nguyen and Münger, 2008; Yan et al., 2010].  
Downstream of the E7-induced deregulation of Rb proteins is the upregulation of the 
phosphoinositide 3-kinase (PI3K)/Akt pathway, which is a central signalling pathway that 
drives cell survival and proliferation. It relies on the phosphorylation-dependent activation of 
Akt that ultimately activates the mammalian target of rapamycin (mTOR) kinase, which 
promotes the transcription of several genes involved in protein synthesis, cell growth, 
motility, metabolism and survival. Indeed, the upregulation of the PI3K/Akt pathway relies 
on the E7-induced degradation of pRb, but E7 can sustain the activation of Akt also by 
impairing the activity of Akt inhibitors, such as protein phosphatase 2A (PP2A) [Pim et al., 
2005]. Thus, E7 acts by targeting different cellular proteins in order to induce the 
transcription of S phase genes and sustain cell growth by forcing the cell to continuously 
divide.  
Finally, E7 promotes also cell migration by acting on proteins of the Rho family, which are 
membrane-bound guanosine triphosphatases (G-proteins) that regulate cytoskeletal 
dynamics and cellular protrusions. In particular, E7 regulates RhoA by impairing the activity 
of p190, a known inhibitor of Rho proteins, and thus enhances cell migration and spreading 
[Todorovic et al., 2014]. Taken together, E7 impairs the functionality of different cell cycle 
regulators and tends to create a positive feedback loop that pushes the infected cell towards 
uncontrolled growth and spreading.  
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Figure 1.8. Molecular mechanisms of cellular immortalization driven by the E7 oncoprotein 
of HR-HPV genotypes. E7 can prevent G1-to-S-phase cycle arrest by inducing the 
degradation of the Rb proteins (pRb, p107 and p130). In addition, E7 can further impair cell 
cycle control through the deregulation of different inhibitors of the cell cycle, such as p21, 
p27, and E2F6, and through the stimulation of pro-proliferative factors, such as cyclins, CDKs 
and the Akt signalling pathway [Moody and Laimins, 2010, modified]. 
 
Physiologically, human cells can sense a condition of uncontrolled proliferation, and as a 
direct consequence, they activate intrinsic apoptotic pathways mainly in a p53-dependent 
manner. Indeed, the activities of E7 induce the increase of p53 transcription. Although E7 
itself can counteract apoptosis by binding to p600 and indirectly inhibiting p53 itself [Huh et 
al., 2005; Massimi and Banks, 1997], its anti-apoptotic ability is not sufficient to avoid cell 
death. Thus, HPV has evolved the ability to finely hijack cellular apoptosis mainly through the 
activities of the second viral oncoprotein, E6.  
 
Similarly to E7, E6 binds to many cellular proteins and induces their proteasome-dependent 
degradation (Figure 1.9). Historically, the best-known target of E6 is p53, which is a major 
tumor suppressor protein in eukaryotic cells that induces cell cycle arrest and DNA repair, or 
alternatively, apoptosis, depending on the extent of cellular damage [Scheffner et al., 1990; 
Werness et al., 1990]. Normally, p53 is expressed at low levels, usually in an inactive form, 
but after cytotoxic/genotoxic stress, the expression of p53 increases and the protein is 
activated by post-translational modifications.  
E6 drives the degradation of p53 through the recruitment of the cellular ubiquitin ligase 
E6AP, which polyubiquitinates p53 [Huibregtse et al., 1993]. Physiologically, E6AP does not 
regulate the endogenous levels of p53 as it is not able to bind to the tumor suppressor 
protein, whose levels are instead regulated by the ubiquitin ligase Mdm2 in healthy cells 
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[Honda and Yasuda, 2000]. However, when E6 binds to E6AP through a direct interaction 
that involves a leucine-rich (LxxLL) motif of E6AP, the heterodimer E6/E6AP can bind to p53, 
thus forming the E6/E6AP/p53 trimeric complex [Martinez-Zapien et al., 2016]. As a 
consequence, p53 is relocated in the cytoplasm where it is efficiently degraded by the 
proteasome machinery, although the precise molecular mechanisms of the 
nucleus/cytoplasm shuttling are still unknown [Stewart et al., 2005].  
In addition, the ability of E6 to induce the degradation of p53 in an E6AP-independent 
manner has been reported, suggesting that the viral protein may recruit other cellular 
ubiquitin ligases [Massimi et al., 2008].  
Finally, E6 can impair p53 suppressor activities also by inhibiting its transactivation. In this 
regard, p300 and ADA3, two cellular proteins that transactivate p53 through post-
translational modifications, are targeted by E6, which induces their inhibition and 
degradation, respectively [Zimmermann et al., 1999; Kumar et al., 2002]. These processes in 
turns prevent the acetylation-dependent activation of p53.  
 
Figure 1.9. Molecular mechanisms of cellular transformation driven by the E6 oncoprotein 
of HR-HPV genotypes. E6 drives malignant transformation mainly by inducing the 
proteasome-dependent degradation of several cellular proteins, such as p53, p300, ADA3, 
PDZ-containing proteins, Bak, and many others. These processes, in turns, sustain cellular 
immortalization, proliferation and block apoptosis [Moody and Laimins, 2010]. 
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Nevertheless, the anti-apoptotic activity of E6 is not restricted to the sole impairment of 
p53-dependent pathways. In fact, the viral oncoprotein can prevent cell death by perturbing 
different cellular proteins important for both intrinsic and extrinsic apoptotic pathways.  
With regard to intrinsic apoptosis, the main effectors are the mitochondria, wherein 
different pro- and anti- apoptotic signalling pathways converge in order to determine 
whether the cell must die or survive. p53 is a crucial player of intrinsic apoptosis, but it is not 
the sole protein that can activate the apoptotic signaling cascade, and thus, other signals 
within the cell can induce apoptosis as a result of E7 activity. In general, when the pro-
apoptotic signals are activated following cell stress, pro-apoptotic proteins, such as Bax or 
Bak, overcome the function of anti-apoptotic mediators and induce the formation of pores 
within the mitochondrial membrane. This event induces the release of inner mitochondrial 
proteins, such as cytochrome c, Smac and Diablo, which promote the apoptotic pathway by 
activating caspase 3 and 7, which will subsequently induce the formation of the 
apoptosome. Accordingly, E6 has been shown to block Bak by inducing its proteasome-
dependent degradation, thus preventing the release of cytochrome c and other pro-
apoptotic factors [Thomas and Banks, 1998].  
With regard to extrinsic apoptosis, infected cells can be targeted to death through 
eǆtƌaĐellulaƌ sigŶals that ďiŶd to theiƌ ƌelatiǀe ͞death ƌeĐeptoƌ͟. AĐĐoƌdingly, three different 
receptors can activate the extrinsic apoptotic pathway upon activation, i.e., tumor necrosis 
factor receptor 1 (TNFR-1), Fas receptor and TNF-related apoptosis inducing ligand (TRAIL) 
receptors. Independently of the specific ligand/receptor involved, these signals induce the 
activation of caspase 8 and 10 within the death inducing signalling complex (DISC), which 
subsequently converges on the activation of caspase 3 and 7. Indeed, E6 has been shown to 
impair all these three signalling pathways by inducing the degradation of several adaptor 
proteins (such as FADD and TRADD) and, especially, the effector caspase, caspase 8 
[Filippova et al., 2002; Filippova et al., 2007].   
Finally, also the upregulation of anti-apoptotic proteins, such as c-IAP2 and survivin, has 
been observed, but this process seems to be a consequence of the E6-mediated activation of 
cellular proliferative and survival pathways [Yuan et al., 2005; Borbely et al., 2006]. 
Taken together, it is clear that HPV has evolved the ability to strongly inhibit cellular 
apoptosis through the multiple activities of the oncoprotein E6. However, E6 does not solely 
serve as an anti-apoptotic effector, but rather as a promiscuous transforming protein that 
can affect a large number of cellular targets and signalling pathways. In fact, E6 not only 
counteract cellular signals that are activated as a consequence of E7 activity, but it also 
enhances and cooperates with E7 in order to promote cell survival and proliferation.  
To exploit these functions, an extremely important characteristic of high-risk E6 
oncoproteins is their ability to bind and degrade cytoplasmic PDZ-containing proteins 
[Massimi et al., 2004]. These are tumor suppressor proteins that orchestrate cytoskeleton 
dynamics, serving as a scaffold for the regulation of several signalling pathways [Humbert et 
al., 2008]. In particular, they are also important for the regulation of cell-to-cell and cell-to-
extracellular matrix (ECM) contacts, wherein they arrange the architecture of tight junctions, 
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adherens junctions and focal adhesions. PDZ-containing proteins generally localize in the 
intracellular side of the plasma membrane, and thus their deregulation involves the cytosolic 
fraction of E6.  
The interaction of high-risk E6 oncoproteins with these cellular tumor suppressor proteins 
occurs through the C-terminal unstructured PBM, which usually folds into a β-sheet when 
bound to a PDZ domain [Zhang et al., 2007]. Although there have been controversial results 
about the effects of E6 on cellular PDZ-containing proteins [Handa et al., 2007; Cavatorta et 
al., 2004; Choi et al., 2014], it is clear that the inhibition of their function is important for 
malignant progression, as it contributes to the impairment of several signalling pathways. 
Whether E6 induces their degradation or their delocalization, loss of PDZ-containing proteins 
in the proper cellular compartment induces the progressive loss of apico-basal polarity, 
which is a characteristic trait of differentiated cells.   So far, up to 12 different PDZ-
containing cellular proteins have been proposed as targets of E6, such as hScrib, hDlg, Multi 
PDZ protein 1 (MUPP1) and Membrane Associated Guanylate kinase homology proteins with 
an Inverted domain structure (MAGI) 1-2-3 [Thomas et al., 2016].   
High-risk E6 oncoproteins show differential binding capacity towards PDZ-containing 
proteins, depending on the viral genotype. These cellular targets are usually negative 
regulators of cell proliferation, and thus their loss correlate with the upregulation of 
proliferative pathways. Accordingly, the E6-mediated impairment of PDZ-containing proteins 
has important effects on PI3K/Akt signalling cascade, and thus E6 can support the activity of 
E7 for the upregulation of the mTOR pathway. The degradation of certain PDZ-containing 
proteins results in the inhibition of phosphatase and tensin homologue (PTEN), which is a 
known inhibitor of Akt kinase [Contreras-Paredes et al., 2006]. In addition, E6 can upregulate 
mTOR and mTOR complexes through other mechanisms of action that do not rely on the 
degradation of PDZ-containing proteins, such as the sustained activation of the epidermal 
growth factor receptor (EGFR), which is upstream of the PI3K/Akt cascade, and the 
degradation of mTOR inhibitors, such as tuberous sclerosis complex 2 (TSC2) [Zheng et al., 
2008; Spangle and Münger, 2013]. This process in turns supports the decrease of p16, a 
known CDK inhibitor, in favour of cyclin D.  
The proliferative activity of E6 involves also the upregulation of other survival pathways, 
particularly Wnt and Hippo.   
The Wnt pathway is a highly conserved signalling cascade extremely important for cellular 
proliferation and differentiation during organ development and tissue homeostasis. When 
the canonical pathway is activated by the binding of Wnt ligand to its receptor Frizzled, the 
phosphorylation of the cytoplasmic mediator Dishevelled induces the accumulation of β-
ĐateŶiŶ iŶ the ŶuĐleus, ǁhiĐh is the ĐeŶtƌal effeĐtoƌ of the WŶt sigŶalliŶg ĐasĐade. NuĐleaƌ β-
catenin can thus promote the transcription of several genes, such as c-jun, c-myc, survivin 
aŶd ĐǇĐliŶ Dϭ. WheŶ the pathǁaǇ is iŶaĐtiǀe, β-catenin is sequestered in the cytoplasm by 
the so-Đalled ͞destƌuĐtioŶ Đoŵpleǆ͟ aŶd is suďseƋueŶtlǇ polǇuďiƋuitiŶated ďǇ the β-TrCP 
uďiƋuitiŶ ligase, ǁhiĐh iŶduĐes β-catenin degradation.   
β-catenin upregulation has been observed in HPV-related cancer samples, and this event 
relies on the activity of E6 [Pereira-Suàrez et al., 2002]. Although the precise molecular 
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mechanism remains unclear, it has been suggested that E6 could induce the degradation of a 
β-catenin inhibitor, i.e., the seven-in-absentia homolog (Siah) protein [Rampias et al., 2010]. 
However, the Wnt pathway is not the sole signalling cascade responsible for the activation of 
β-ĐateŶiŶ. The aĐtiǀatioŶ of PIϯK/Akt sigŶalliŶg pathǁaǇ ĐaŶ iŶduĐe β-catenin nuclear 
accumulation through the inhibition of glycogen synthase kinase-ϯβ ;G“KϯβͿ, ǁhiĐh is a 
component of the destruction complex [Wu and Pan, 2010].   
Furthermore, also the Hippo-transducers Yes-associated protein (YAP) and Trascriptional 
coactivator with PDZ-ďiŶdiŶg ŵotif ;TA)Ϳ aƌe poteŶt ƌegulatoƌs of β-catenin. In fact, a fine 
interplay between Wnt signalling and YAP/TAZ activity exists. YAP/TAZ have been shown to 
be crucial components of the cytoplasmic destruction complex, instrumental for the 
ƌeĐƌuitŵeŶt of β-TƌCP uďiƋuitiŶ ligase, iŶ oƌdeƌ to pƌoŵote β-catenin, as well as TAZ, 
degradation [Azzolin et al., ϮϬϭϰ]. Thus, aĐtiǀe β-catenin associates to active YAP/TAZ, which 
all relocate within the nucleus to promote the transcription of target genes, and vice versa, 
since YAP/TAZ are activated by Wnt growth factors.   
YAP and TAZ are two transcriptional coactivators that promote the transcription of genes 
important for proliferation, survival and stemness, which are transcribed by TEAD and 
Activator Protein-1 (AP-1) transcription factors. Indeed, active YAP and TAZ accumulate 
within the nucleus wherein they bind to TEAD and AP-1 proteins [Zanconato et al., 2015]. 
Phosphorylation of YAP and TAZ induces their inactivation and cytoplasmic retention, with 
concomitant TAZ and, to a lesser extent, YAP degradation.   
In the last years, YAP and TAZ have become central players of regenerative medicine and 
cancer biology, as they seem to play a crucial role during organ development and 
regeneration, as well as for cancer progression, metastasis and cancer stem cell 
reprogramming [Zanconato et al., 2016]. Indeed, their central role accounts for the fine and 
complex framework of regulatory signals that converge on YAP and TAZ [Piccolo et al., 2014]. 
Their activity can be stimulated by the Wnt signalling, G protein-coupled receptors (GPCRs), 
and can be finely regulated by mechanical forces imposed by the environmental extra-
cellular matrix, which can either stimulate or repress YAP and TAZ, depending on the 
stiffness of the ECM. Furthermore, structural complexes of the apico-basal polarity 
negatively regulate YAP/TAZ activity, recapitulating the mechanisms of anti-proliferative 
contact inhibition. Similarly, also the Hippo pathway, which is a highly conserved signalling 
cascade composed of several kinases, such as LATS1-2, MST1-2 and NF2, leads to YAP/TAZ 
inhibition, following the activation of the phosphorylation cascade.   
Intriguingly, E6 can affect these pathways by impairing different regulatory proteins and 
perturbing the signalling cascades in multiple ways and at different steps. As already 
ŵeŶtioŶed, Eϲ ĐaŶ iŶduĐe the upƌegulatioŶ of β-ĐateŶiŶ ďǇ degƌadiŶg a β-catenin inhibitor, 
ďut β-catenin upregulation can be accomplished also through the E6/E7-mediated induction 
of the PI3K/Akt signalling [Contreras-Paredes et al., 2006; Rampias et al., 2010]. 
Furthermore, a recent study reported the E6-mediated induction of YAP in cervical cancer 
cells as a result of SOCS6 degradation, a known YAP inhibitor [He et al., 2015]. Additionally, 
this process sustains the upregulation of EGFR and the expression of EGFR ligands, such as 
TGF-α aŶd A‘EG.  
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Thus, the activities of E6 can induce cell survival and proliferation by altering many 
interconnected signalling pathways.  
In addition to the aforementioned roles, E6 has important effects also on human telomerase 
(hTERT), innate immunity and Notch signalling pathway.   
HuŵaŶ teloŵeƌase is a ƌiďoŶuĐleopƌoteiŶ that eǆteŶds the ϯ͛ eŶds of liŶeaƌ Đhƌoŵosoŵes 
during eukaryotic DNA replication through the use of an RNA template. Its activity is 
extremely important to avoid the loss of genetic information and to prevent recombination 
at the termini. In normal somatic cells, hTERT is quiescient, but it is usually reactivated in 
cancer cells [Janknecht, 2004].   
E6 can induce hTERT activity and this process requires the interaction with E6AP. The E6-
mediated induction of hTERT can occur through at least two different mechanisms: the 
degradation of NFX1-91, which is a transcriptional repressor that prevents hTERT 
transcription, and the association of E6 with c-myc, which induces the c-myc-mediated 
transcription of hTERT [Veldman et al., 2003; Gewin et al., 2004]. Both activities thus 
modulate the transcription of hTERT leading to its upregulation.  
E6 can also modulate the transcription of genes involved in the innate immune response-
related pathways. The viral oncoprotein can interact with Toll-like receptor-9 (TLR-9) and 
Interferon regulatory factor-3 (IRF-3), inhibiting their transcription and transactivation 
ability, respectively [Ronco et al., 1998; Hasan et al., 2007]. As a direct consequence, the 
induction of interferon-β aŶd the production of cytokines are prevented, thus hiding the cell 
from the activity of leukocytes of the innate immune system.  
 
With regard to Notch signalling pathway, controversial results have been reported about the 
activity of E6 towards this signalling cascade.   
Notch is another highly conserved cell signalling pathway extremely important during 
embryonic development. It has multiple functions depending on the tissue involved and can 
induce either cell differentiation or self-renewal abilities. In the context of adult epidermal 
cells, Notch is usually activated in order to induce epidermal stem cell proliferation and 
differentiation. The signalling cascade relies on the activation of Notch receptors following 
the binding with a Notch protein, such as Jagged and Delta-like ligands, which are 
transmembrane proteins expressed on the cell surface of neighbouring cells. Following their 
iŶteƌaĐtioŶ, the iŶtƌaĐellulaƌ poƌtioŶ of NotĐh ƌeĐeptoƌ is Đleaǀed ďǇ γ-secretase that releases 
the Notch intracellular domain (NCID), which is translocated into the nucleus to support 
gene transcription. This process allows the fine regulation of cell fate in a cell-to-cell contact 
manner, depending on the pattern of Notch ligands/receptors expressed on the cell surface. 
Whether E6 upregulates or blunts Notch signalling still remains an open question.  
Some authors have indeed observed the E6-mediated upregulation of Notch-1 receptor 
mRNA levels [Daniel et al., 1997], but other studies reported the decrease of Notch-1 in 
cervical cancer cell lines [Talora et al., 2002]. Nevertheless, to a certain extent, the activity of 
E6 seems to perturb Notch signalling in a manner that is probably dependent on the 
interplay among other signalling pathways and the overall malignant genotype of the 
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transformed cell. Taken together, it is clear how the activities of E6 can deeply perturb the 
cellular environment and support the proliferative function of E7.  
 
In a more general point of view, E7 can be considered the immortalizing factor of HPV, as it 
extends the life span of the infected cells. Indeed, E7 can efficiently induce benign epidermal 
hyperplasias in mice [Song et al., 2000]. However, the transforming potential of E7 is quite 
weak, and the protein seems to have a crucial role at the promotion stage of cancer 
development, when cells are induced to grow, rather than at the progression stage. Vice 
versa, E6 acts weakly at the promotion stage, but has strong transforming potential and 
efficiently supports cancer progression. 
However, as mentioned in Paragraph 1.6, the continuous activity of these viral oncoproteins 
is necessary but not sufficient for malignant transformation. Accordingly, the ability of the 
E6/E7-expressing cells to remain invisible to the immune system, while continuously 
proliferating, allows the accumulation of somatic mutations, which is the essential co-factor 
that drives cellular transformation. In fact, genomic instability plays a key role in HPV-
induced carcinogenesis and actively promotes cellular transformation. This process is in turn 
a direct consequence of E6/E7 activities, since they increase genomic instability as a result of 
Akt upregulation, p53 degradation and pRb inhibition, allowing the cell to tolerate the 
progressive accumulation of genetic mutations and genomic abnormalities. Therefore, the 
role of HPV oncoproteins is to initiate a complex mechanism of intracellular alterations, 
perturbing many important signalling pathways. This process results in the progressive 
instability of the host genome, which accumulates gene mutations following the 
uncontrolled cellular proliferation, and slowly transforms the infected cell into a cancer cell 
(Figure 1.10). 
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Figure 1.10. Schematic representation of the interplay between the activities of HR-HPV E6 
and E7 for the deregulation of cellular signalling pathways. The activities of the two viral 
oncoproteins have profound effects on cellular proliferation, DNA repair, senescence, 
apoptosis and gene expression, inducing genomic instability and cellular transformation 
[Groves and Coleman, 2015, modified]. 
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1.6.2 E6 and E7: molecular targets for therapeutic intervention. 
 
The incontrovertible addiction of cancer cells to the sustained activity of HPV oncogenes is a 
remarkable characteristic that has intrinsic potential for the treatment of HPV-induced 
cancers. Indeed, the pivotal role of E6 and E7 for cancer development directly addresses the 
attention to these two proteins as primary targets for the development of anticancer drugs 
[D͛Aďƌaŵo aŶd AƌĐhaŵďault, ϮϬϭϭ]. 
E6 and E7 possess no enzymatic activity and both proteins trigger their functions exclusively 
through protein-protein interactions (PPIs). As a direct consequence, a possible strategy to 
counteract the activity of these two proteins is the development of small molecules that act 
as PPI inhibitors. The purpose of small-molecule drug discovery is to seek for compounds 
able to interfere with the pathogenic activity of the targeted protein, with minimal 
alterations in cellular physiology. With regard to PPIs, this is possible especially when the 
exogenous protein drives the interactions through accessible pockets or cavities on its 
surface, where small molecules can be designed to fit with high affinity. However, PPI targets 
have traditionally been ignored by small-molecule drug developers, despite their therapeutic 
relevance and untapped abundance, largely because of technological hurdles. Scientific 
advances recently permitted to overcome these challenges [Mullard, 2012]. Indeed, since 
few years ago, many big pharmaceutical companies started working on promising drugs such 
as navitoclax (Abboth/Genentech) and obatoclax (Teva), both of which are now 
commercialized as anticancer agents that inhibit the function of the prosurvival BCL-2 family 
proteins by blocking key PPIs [Mullard, 2012]. 
So far, despite being attractive molecular targets from a biological point of view, E6 and E7 
proved to be refractory to the inhibition by small-molecule compounds, possibly for their 
small size, but especially because of the lack of detailed stƌuĐtuƌal iŶfoƌŵatioŶs [D͛Aďƌaŵo 
and Archambault, 2011]. This has forced researchers to look for anti-HPV compounds only 
through high-throughput screening techniques, by a classical drug discovery approach [Fera 
et al., 2012; Yuan et al., 2012; Malecka et al., 2014]. However, in recent years, several 
structural models of E6 and E7 have been published [Ohlenschlager et al., 2006; Liu et al., 
2006; Zanier et al., 2013; Martinez-Zapien et al., 2016].   
Detailed structural informations allow the rational screening of compounds by in silico 
modeling, through a process known as structure-based drug design. The advantage of this 
approach is the preliminar selection of candidate molecules that are complementary in 
shape and charge to the biomolecular target with which they should interact. This process 
allows the restriction of the number of molecules to be tested and the knowledge-based 
refinement of the hits. 
Accordingly, the availability of high-resolution NMR and crystal structures of E6 and E7 
allows the rational design of anti-E6/E7 compounds. However, with regard to the structure 
of E7, the unfoldedness of its N-terminal domain, through which many crucial PPIs occur, 
strongly impairs the possibility to develop small-molecule inhibitors directed against those 
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PPIs and, indeed, structural informations of the N-terminal domain of E7 are so far 
unavailable [Garcia-Alai et al., 2007(a)]. In addition, E6, rather than E7, has been often 
depicted as the main oncoprotein to be targeted for cancer treatment because its 
suppression reactivates p53-mediated pathways [Manzo-Merino et al., 2013]. Indeed, many 
studies showed that silencing, deregulation or inhibition of E6 lead to apoptosis and 
malignant cell clearance with a substantial reduction in tumor size in animal models [Gu et 
al., 2006; Jonson et al., 2008]. Thus, E6 represents a major fascinating target for the 
development of anti-HPV drugs for therapeutic intervention. Inhibition of E6 oncotic activity 
could be achieved through the identification of small molecules able to target specific 
regions on E6 surface involved in PPIs crucial for the degradation of p53 or other onco-
suppƌessoƌ pƌoteiŶs [D͛Aďƌaŵo aŶd AƌĐhaŵďault, ϮϬϭϭ]. 
 
 
1.6.3 Strategies for the development of anti-E6 compounds. 
 
The physico-chemical and structural characteristics of E6 are key elements in order to 
understand the mechanisms through which E6 fulfills its functions. Intriguingly, such a small 
protein can induce the degradation of a multitude of cellular targets. Whether this is 
possible through structural rearrangements, common interaction surfaces, or through the 
recruitment of different ubiquitin ligases remains largely unclear.   
As mentioned in Paragraph 1.6.2, structural informations are extremely important for 
structure-based drug design. So far, several NMR and crystal structures of E6 have been 
published, shedding light on the molecular interactions occurring with E6AP, p53 and PDZ-
containing proteins [Charbonnier et al., 2001; Zhang et al., 2007; Liu et al., 2007; Zanier et 
al., 2013; Martinez-Zapien et al., 2016]. Although E6 has a plethora of interacting partners, 
E6AP was shown to be crucial for the degradation of many cellular proteins, including p53 
[Massimi et al., 2004]. The interaction involves a leucine-rich (LxxLL) α-helix of E6AP that 
binds within a cavity formed by the two zinc-finger domains of E6, through polar and 
hydrophobic contacts (Figure 1.11). E6 cannot bind p53 in the absence of E6AP and, vice 
versa, E6AP cannot bind p53 in the absence of E6 [Ansari et al., 2012]. The formation of the 
complex thus requires all three elements in such a way that the interaction with E6AP 
tightens the conformation of E6, keeping the N-terminal and C-terminal domains in close 
contact, and this event subsequently induces the binding to p53. The three leucine residues 
of the LxxLL motif of E6AP accommodates within a hydrophobic core formed by N-terminal 
residues of E6 (mainly Y32, L50, L67, and Y70). However, the interaction is crucially driven by 
arginine side chains of E6 on the surrounding area that work as keystones for the 
architecture of the complex, i.e., R10, R55, R102 and R131. In addition, other polar residues 
of Eϲ seeŵ to ďe iŶǀolǀed iŶ the iŶteƌaĐtioŶ, seƌǀiŶg as ͞ƌeadeƌs͟ iŶ oƌdeƌ to disĐƌiŵiŶate 
differences in the composition of the LxxLL motifs [Zanier et al., 2013].  
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Figure 1.11. Crystal structure of HPV16 E6 bound to the LxxLL peptide of E6AP (green), 
showing the formation of a deep pocket on E6 protein surface (pink) for the accommodation 
of the helical-motif of E6AP, which binds to the viral oncoprotein through hydrophobic and 
polar interactions (insert) [Zanier et al., 2013, modified].  
 
 
Once formed, the heterodimeric complex E6/E6AP can sequester p53, inducing its 
polyubiquitination and proteasome-dependent degradation. According to the last published 
structural model [Martinez-Zapien et al., 2016], p53 binds on a surface that spans both E6 
zinc-finger domains, which are tightened by the interaction with E6AP, as previously 
discussed (Figure 1.12). This event explains the need of the E6/E6AP complex formation 
prior to the binding to p53. However, the latest crystal structure was solved using only the 
LxxLL motif of E6AP fused to the maltose-binding protein (MBP), and thus, no structural 
information about the overall contribution of E6AP to the trimeric complex is available. 
Anyway, p53 binds to a cleft formed by the E6N and E6C domains and the interaction involves 
the p53 core domain, but at a site different from the DNA-binding region of p53. The binding 
interface on E6 surface can be divided into three sub-interfaces: I, II and III. The sub-interface 
I involves polar interactions on the N-terminal part of the E6N domain, corresponding to the 
αϭ-helix, particularly through residues E7 and R8. The sub-interface II mainly involves the αϮ-
helix of the E6N domain and both hydrophobic and polar contacts occur between E6 and 
p53, particularly through residues Y43, D44 and F47. The sub-interface III involves only 
hydrophobic interactions occurring on the E6C domain, particularly through residues L100 
and P112. 
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Figure 1.12. Crystal structure of the HPV16 E6/E6AP/p53 ternary complex (orange, green 
and purple, respectively), showing the formation of the p53 binding interface as a result of 
the interaction between E6 and E6AP. As shown, p53 binds to E6 on a cleft formed by three 
sub-interfaces (blue) spanning both the N-terminal and C-terminal domains of E6, which are 
tightened by the binding of the LxxLL motif of E6AP on a cavity (green) on E6 protein surface 
(HL: helix linker) [Martinez-Zapien et al., 2016]. 
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Intriguingly, about half of the residues of the sub-interface II involved in the interaction with 
p53 were observed to be crucial also for E6 self-association [Zanier et al., 2012]. Through 
NMR studies, Zanier and coworkers published a model in which two E6 monomers interact in 
a face-to-face manner through their N-terminal domains (Figure 1.13). Noteworthy, the 
residues that seem to be crucial for the homodimerization reside in a small hydrophobic 
poĐket at the ďottoŵ of αϮ-helix, mainly composed by I23, A24, Y43 and F47, where the side 
chain of F47, located in the other monomer, fits, and vice versa. Interestingly, these amino 
acids are highly conserved among high-risk mucosal HPV strains.   
 
Figure 1.13. Haddock model structure of the HPV16 E6N homodimer (left) and views of the 
homodimer interface (right), illustrating the orientation of the hydrophobic residues of an 
E6N monomer (purple) relative to the other (green) [Zanier et al., 2012]. 
 
Although the role of the dimeric form of E6 remains so far elusive, contrasting results have 
been published about the involvement of the dimerization for the productive degradation of 
p53 [Zanier et al., 2012; Martinez-Zapien et al., 2016]. Thus, the question whether the 
dimerization is needed in order to induce the degradation of p53 remains unanswered. In 
fact, Zanier and coworkers proposed a model in which the self-association of E6 is a crucial 
step for the degradation of p53. This hypothesis was mainly supported by their previous 
observation that the introduction of polar residues in this hydrophobic region (such as a 
phenylalanine-arginine substitution at position 47) abolished p53 degradation activity while 
retaining the ability of E6 to interact with both p53 and E6AP in cell-based pull-down assays 
[Ristriani et al., 2009].  
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However, in 2016 the same group published contrasting results, as they reported that 
mutant E6 F47R was not able to bind p53, thus explaining the inability to degrade p53 as a 
result of its impaired binding capacity [Martinez-Zapien et al., 2016]. Indeed, F47 is one of 
the key residues of sub-interface II and the introduction of a polar amino acid (i.e., arginine) 
in this hydrophobic surface might substantially impair the binding between E6 and p53. 
Accordingly, the authors concluded that E6 dimerization and E6-p53 interaction are likely 
two distinct processes that occur on partly overlapping surfaces. 
In addition to the aforementioned NMR and crystal structures, detailed structural 
informations about the PBM-PDZ domain interaction are also available [Liu et al., 2007; 
Zhang et al., 2007]. Binding of E6 to PDZ-containing proteins relies on the positioning of the 
C-terminal 7-amino-acid peptide R-R/T-E-T-Q/E-V/L-L of high-risk E6 oncoproteins on a 
shallow cavity on the surface of PDZ domains (Figure 1.14). It has been observed that the 
interaction directly involves six of the seven residues of the PBM [Zhang et al., 2007]. 
Furthermore, differences in the amino acid composition of the PBMs among different viral 
genotypes, together with the variability of the three residues upstream of the PBM, 
modulate target specificity [Thomas et al., 2016]. 
 
 
Figure 1.14. Ribbon representation of the C-
terminal PBM of HPV18 E6 bound to the PDZ 
domain of human Disc Large, coloured 
according to the electrostatic potential. 
Residues highlighted in orange are directly 
involved in the binding with the PBM of E6. 
Positive potential is shown in blue, negative 
potential in red [Liu et al., 2007]. 
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According to the published structural models, different strategies can be envisaged to design 
effective inhibitors of E6. 
The first and so far most popular strategy is the targeting of E6/E6AP binding interface. 
Indeed, disrupting this interaction has the intrinsic advantage of targeting a cavity on E6 
protein surface, which ideally enables the development of potent and specific E6 inhibitors. 
Although this approach has been pursued by several groups, with overall good results [Baleja 
et al., 2006; Cherry et al., 2013], it has been questioned that this could not be an exhaustive 
strategy because some functions of E6 with respect to p53 inhibition seem to be performed 
in the absence of E6AP binding [Camus et al., 2007; Massimi et al., 2008]. In addition, it has 
been suggested that while drugs designed to interact with the E6AP (LxxLL peptide)-binding 
pocket of E6 could prevent the E6AP-dependent degradation of p53, they could also stabilize 
E6 expression, with difficult-to-predict consequences [Ansari et al., 2002]. 
Another possible strategy is the targeting of PBM-PDZ domain interactions. Although this 
approach has intrinsic potential with regard to the inhibition of E6 transforming activities, 
only one report has been published about the successful inhibition of this interaction 
[Ramirez et al., 2015]. However, the possibility to impair PBM-PDZ recognition was possible 
only through the use of a chimeric inhibitor protein, wherein a recombinant PDZ domain was 
expressed in HPV-positive cell lines, functioning as a competitor against the natural 
interactions between E6 and cellular PDZ-containing proteins. As a matter of fact, no reports 
involving small-molecule inhibitors have been successfully published, most likely due to the 
difficulty in the identification of compounds that could specifically block E6-PDZ domain 
binding without affecting normal cellular PDZ domain-dependent interactions.  
A third strategy is the targeting of E6-p53 binding interface. Indeed, this represents a 
fascinating target for the development of anti-E6 compounds. Anyhow, this strategy has 
been so far hampered by the lack of a crystal structure of the E6/E6AP/p53 trimeric complex, 
which has become available only very recently [Martinez-Zapien et al., 2016]. Intriguingly, 
the p53-binding cleft on E6 protein surface represents a potential binding site for small-
molecule inhibitors. In addition, key residues on the p53-binding cleft appear to be highly 
conserved among high-ƌisk geŶotǇpes, paƌtiĐulaƌlǇ the αϮ-helix corresponding to the sub-
interface II, which drives also E6 self-association. Although this latter interaction remains 
poorly characterized, targeting this binding interface could represent a novel strategy for the 
development of anti-E6 compounds. 
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2. Aim 
 
HR-HPVs are still a major cause of epithelial cancers worldwide, being the aetiological agents 
of cervical, oropharyngeal and anogenital cancers. Although a vaccination program has been 
started to prevent virus infection, there is still a need of specific treatments for patients 
already infected and at a high risk for developing HPV-associated malignant tumors. 
Furthermore, the vaccination program, if globally implemented, would still take up to 20 
years to have a significant impact on the incidence of HPV-related cancers, and the 
accessibility in many developing countries, in terms of cost and logistic, will remain an issue. 
Finally, no specific anti-HPV drugs are commercially available yet.  
 
The viral oncoprotein E6 is the major player responsible for cellular transformation during 
HR-HPV-induced cancer progression, and thus represents a fascinating target for the 
development of anti-HPV drugs. Although deeply studied since the early Nineties, the 
oncoprotein E6 possesses intriguing transforming abilities, particularly because of its very 
small dimensions (being composed of 151 amino acids), and still represents an eclectic and 
versatile protein able to impair several signalling pathways.   
Since the initial discovery of the ability of E6 to degrade p53 [Scheffner et al., 1990], the viral 
oncoprotein was always thought to act as a monomer in the infected cell in order to induce 
the degradation of its cellular targets. However, recent studies on E6 demonstrated that it 
can also self-associate in homo-dimers in vitro through a highly conserved interaction 
surface (corresponding to the N-terminal α2-helix) [Zanier et al., 2012], which was later 
observed to be important also for the binding of E6 to p53 [Martinez-Zapien et al., 2016]. 
Although the homodimerization of E6 remains an event poorly characterized, targeting the 
PPIs driven by this highly conserved surface on the viral oncoprotein may represent a novel 
strategy for the development of anti-HPV drugs. 
 
Thus, the goals of this PhD project were the investigation of the existence of HPV16 E6 as a 
homodimer in a cellular context, the characterization of its biological importance relative to 
E6 transforming activities and the identification of compounds able to target the α2-helix of 
the N-terminal domain of the viral oncoprotein. 
 
With regard to the study of E6 dimerization, different protein-protein interaction assays 
have been employed:  
- Bioluminescence Resonance Energy Transfer (BRET) assay, in which either YFP or Renilla 
Luciferase (RLuc) are fused to the viral protein. When coelenterazine is added, RLuc-tagged 
E6 emits a blue luminescent light. If a second E6 molecule, carrying YFP, interacts (through 
the dimerization of E6), the energy is transferred producing a yellow signal.  
   
48 
 
- ELISA-based in vitro assay, in which recombinant purified E6 molecules have been used to 
study the site-specific self-association of the viral oncoprotein. We coated the surface of 
wells of microtiter plates with recombinant E6N proteins and, by incubating a second 
recombinant E6N protein, we measured the direct interaction between the N-terminal 
domains of E6. 
 
With regard to the functional characterization of the dimeric form of E6, different cell-based 
assays have been developed, transfecting HPV-negative cells with either wild-type or 
dimerization-defective E6 mutants and monitoring the changes in the endogenous levels of 
different cellular proteins, such as p53, Scribble, and TAZ.  
 
Finally, two different in silico screenings of small-molecule libraries have been performed to 
find compounds able to target the α2-helix of the N-terminal domain of HPV16 E6. The hits 
emerged from the screenings were tested, first in the ELISA-based E6N homodimerization 
assay to assess their ability to impair E6 self-association, and subsequently in cell-based 
assays to evaluate their ability to block the E6-mediated degradation of p53 and their ability 
to specifically target HPV-positive cells in cell viability and cell proliferation assays. 
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3. Materials and Methods 
 
3.1 Materials. 
 
3.1.1 Compounds. 
 
Anti-E6 compounds selected from the virtual screenings were purchased from Specs 
chemistry database (Zoetermeer, The Netherlands, www.specs.net).  
Compound powders were kept at 4°C in the dark. Upon resuspension in DMSO (Sigma-
Aldrich), 50 mM stocks solutions were stored at -20°C, protected from light. 
 
 
3.1.2 Proteins. 
 
Glutathione S-Transferase (GST), 6 histidine-tagged (6his)-PA239-716 (representing the C-
terminal domain of Polymerase Acidic protein from influenza A virus) and UL44 (DNA 
polymerase processivity factor from human cytomegalovirus) were expressed in E. coli 
BL21(DE3)/pLysS strain and purified through affinity chromatography as previously described 
[Loregian et al., 2004; Massari et al., 2013].  
GST-E6N, 6his-E6N and untagged E6N proteins were expressed and purified as described in 
Paragraph 3.2.13 
 
 
3.1.3 Oligonucleotides. 
 
Synthetic oligonucleotides for gene cloning, mutagenesis and DNA sequencing were 
purchased from Promega and are listed in Tables 3.1, 3.2, 3.3 and 3.4.  
siRNA oligos for gene silencing, which are dsRNA oligos with overhanging dTdT, and control 
(scrambled) siRNA were purchased from Thermo Fisher Scientific and Qiagen, respectively, 
and are listed in Table 3.5. 
50 
 
Table 3.1 Oligonucleotides for ligase-dependent cloning 
Oligonucleotide “eƋueŶĐe ϱ͛ to ϯ͛ 
E6 pET28 FOR TTTATGAATTCATGTTTCAGGACCCACAGG 
E6 pET28 REV TAAAGCGGCCGCTTACAGCTGGGTTTCTCTACG 
E6N pET28 REV TAAAGCGGCCGCTTAGCTGTAATGTCTATACTC 
E6 pD15 FOR AAAAAACTCGAGATGTTTCAGGACCCACAGG 
E6 pD15 REV TAAAAAACGCGTTTACAGCTGGGTTTCTCTACG 
E6N pD15 REV TAAAAAACGCGTTTAGCTGTAATGTCTATACTC 
 
Table 3.2 Oligonucleotides for Gateway® cloning 
Oligonucleotide “eƋueŶĐe ϱ͛ to ϯ͛ 
E6 attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTCGATGTTTCAGGACCCACAGGAGCG 
E6 attB2 STOP GGGGACCACTTTGTACAAGAAAGCTGGGTCTTACAGCTGGGTTTCTCTACGTG 
E6 attB2 noSTOP GGGGACCACTTTGTACAAGAAAGCTGGGTCCAGCTGGGTTTCTCTACGTGTTC 
E6 NT attB2 STOP GGGGACCACTTTGTACAAGAAAGCTGGGTCTTAGCTGTAATGTCTATACTCACTAA
TTTTAG 
E6 NT attB2 noSTOP GGGGACCACTTTGTACAAGAAAGCTGGGTCGCTGTAATGTCTATACTCACTAATTTT
AG 
p53 attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTCGATGGAGGAGCCGCAGTCAGATCC 
p53 attB2 STOP GGGGACCACTTTGTACAAGAAAGCTGGGTCTTAGTCTGAGTCAGGCCCTTCTG 
 
Table 3.3 Oligonucleotides for site directed mutagenesis 
Oligonucleotide “eƋueŶĐe ϱ͛ to ϯ͛ 
E6 S16C FOR CCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAAC 
E6 S16C REV GTTGTTTGCAGCTCTGTGCATAACTGTGGTAACTTTCTGG 
E6 S51C FOR GACTTTGCTTTTCGGGATTTATGCATAGTATATAGAGATGGG 
E6 S51C REV CCCATCTCTATATACTATGCATAAATCCCGAAAAGCAAAGTC 
E6 F47R FOR CGTGAGGTATATGACTTTGCTCGTCGGGATTTATGCATAGTATATAGAG 
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E6 F47R REV CTCTATATACTATGCATAAATCCCGACGAGCAAAGTCATATACCTCACG 
E6 mut donor FOR CAACAGTTACTGCGACGTGAAGTATATGACTTTGCTTTTCGG 
E6 mut donor REV CCGAAAAGCAAAGTCATATACTTCACGTCGCAGTAACTGTTG 
E6 F47R mut donor FOR CAACAGTTACTGCGACGTGAAGTATATGACTTTGCTCGTCGG 
E6 F47R mut donor REV CCGACGAGCAAAGTCATATACTTCACGTCGCAGTAACTGTTG 
E6 F47R mut donor Y43E FOR GTTACTGCGACGTGAAGTAGAAGACTTTGCTCGTCGGG 
E6 F47R mut donor Y43E REV CCCGACGAGCAAAGTCTTCTACTTCACGTCGCAGTAAC 
 
Table 3.4 Oligonucleotides for DNA sequencing 
Oligonucleotide “eƋueŶĐe ϱ͛ to ϯ͛ 
pD15 seq FOR TGGCGACCATCCTCCAAA 
pD15 seq REV TATGCTAGTTATTGCTCA 
pET28 seq FOR AATACGACTCACTATAGG 
pET28 seq REV CTAGTTATTGCTCAGCGGTGG 
HCMV seq FOR CGCAAATGGGCG  
pDONR seq FOR TAACGCTAGCATGGATCTC 
pDONR seq REV GCAATGTAACATCAGAGAT 
pDEST seq TAATACGACTCACTATAGGG 
pcDNA seq TAGAAGGCACAGTCGAGG 
pT-REX seq CGCAAATGGGCGGTAGGCGTG 
 
Table 3.5 Oligonucleotides for gene silencing 
siRNA Target gene “eƋueŶĐe ϱ͛ to ϯ͛ Reference 
16E6-191 HPV16 E6 UGUGUGUACUGCAAGCAAC Koivusalo et al., 2005 
18E6/E7-755 HPV18 E6/E7 CCACAACGUCACACAAUGU Kuner et al., 2007 
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3.1.4 Plasmids. 
 
p513 plasmid is a pSG5-derived vector for protein expression in eukaryotic cells, containing: 
Simian Virus 40 (SV40) promoter/enhancer and polyadenylation site for efficient 
recombinant protein production in transfected cells, ColE1 origin of replication for high-copy 
number replication in E. coli strains, ampicillin resistance gene for selection of transformed 
bacteria and a Multi Cloning Site (MCS) for gene cloning. 
pcDNA3 plasmid is used to express recombinant proteins in eukaryotic cells and contains: 
human cytomegalovirus (HCMV) promoter/enhancer and polyadenylation site for high 
expression levels in transfected cells, ColE1 origin of replication for high-copy number 
replication in E. coli strains, ampicillin resistance gene for selection of transformed bacteria 
and an MCS for gene cloning. 
pcDNA3-derived plasmid for Gateway® cloning is an engineered destination vector that lacks 
any MCS but allows gene cloning through the bacteriophage lambda site-specific 
recombination system (see also Paragraph 3.2.1.5). It contains a ccdB gene that allows the 
selection of E. coli following recombination and transformation. Recombinant proteins are 
expressed with N-terminally tagged Renilla Luciferase (RLuc). 
pDEST destination plasmids are used to express Yellow Fluorescent Protein (YFP)- or FLAG- 
tagged proteins in eukaryotic cells and contain: HCMV promoter/enhancer and 
polyadenylation site, ColE1 origin of replication, ampicillin resistance gene, ccdB gene and 
site-specific recombination sequences for Gateway® Technology. Recombinant proteins are 
expressed in transfected cells with YFP or FLAG® epitope tag fused either at the N-terminus 
or at the C-terminus of cloned gene, depending on the specific pDEST vector used for gene 
cloning. 
pT-REX plasmid is a pcDNA4-derived destination vector for Gateway® Technology 
containing: HCMV promoter/enhancer and polyadenylation site, ColE1 origin of replication, 
ampicillin resistance gene, ccdB gene and site-specific recombination sequences for 
Gateway® cloning technique. Recombinant proteins are expressed with RLuc fused at the C-
terminus of cloned gene. 
pDONR207 plasmid is an entry vector used to transfer any gene of interest into the 
previously described destination vectors (pcDNA3, pDEST and pT-REX) through Gateway® 
site-specific recombination system. It contains: pMB1 origin of replication, gentamicin 
resistance gene and ccdB gene for double selection of E. coli following recombination and 
transformation. 
pET28a+ plasmid is a vector used for protein expression in prokaryotic cells. It allows the 
expression of recombinant proteins with an N-terminal 6 histidine-tag (6his) for protein 
purification. It contains: T7 RNA polymerase promoter, kanamycin resistance gene for E. coli 
selection and a MCS for gene cloning. 
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pDEST15 plasmid allows the expression of recombinant proteins in E.coli strains tagged with 
GST at the N-terminus of cloned gene for purification purposes. It contains a T7 RNA 
polymerase promoter, an ampicillin resistance gene and a MCS for gene cloning. 
pCS2+ plasmid is a pBluescript II-derived vector for protein expression in eukaryotic cells, 
containing: simian CMV promoter, two MCSs for gene cloning, one upstream and one 
downstream the SV40 polyadenylation site, and an ampicillin resistance gene. 
 
 
3.1.5 Cell Lines. 
 
HEK 293T: HPV-negative human embryonic kidney epithelial cell line derived from a fetus, in 
which the SV40 T-antigen was inserted. These cells were used for their easy transfectability 
and abundant exogenous protein production. 
C33A: HPV-negative human epithelial cancer cell line, derived from cervical cancer of a 66-
year old Caucasian female. These cells are defective for both p53 and pRb function. 
H1299: HPV-negative human epithelial cancer cell line, derived from non-small cell lung 
cancer of a 43-year old male. These cells are p53-/- due to a homozygous partial deletion of 
the TP53 gene. 
Hela: HPV-positive human epithelial cancer cell line, derived from a cervical adenocarcinoma 
of a 31-year old female. These cells contain an integrated copy of HPV18 genome. 
CaSki: HPV-positive human epithelial cancer cell line, derived from a metastatic site of a 
cervical carcinoma belonging to a 40-year old female. These cells contain integrated copies 
of HPV16 genome (up to 600 copies per cell) as well as sequences related to HPV18. 
SiHa: HPV-positive human epithelial cancer cell line, derived from a grade II cervical 
squamous cell carcinoma of a 55-year old female. These cells contain an integrated copy of 
HPV16 genome (1-2 copies per cell). 
HFF: Human Foreskin Fibroblasts from the America Type Culture Collection (ATCC). 
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3.1.6 Bacterial strains. 
 
E. coli DH5α: strain of Escherichia coli containing multiple mutations that enable high-
efficiency transformations. This strain was used for the replication and purification of the 
aforementioned plasmids.  
E. coli BL21(DE3)/pLysS: strain of Escherichia coli containing an IPTG-inducible gene for T7 
RNA polymerase and a pLysS plasmid, which encodes T7 lysozyme. T7 lysozyme reduces the 
basal expression of exogenous proteins by inhibiting the T7 RNA polymerase. This strain was 
used for the in vitro expression and purification of the aforementioned recombinant 
proteins. 
Transformed bacteria were grown in liquid Luria Bertani (LB) medium (1% tryptone, 1% NaCl, 
0.5% yeast extract) or, alternatively, on solid LB plates (supplemented with 1.5% agar), with 
the appropriate antibiotic. 
 
 
3.1.7 Antibodies. 
 
3.1.7.1 Primary antibodies. 
 
Santa Cruz Biotechnology 
Goat polyclonal anti-HPV16 E6 (N-17) [catalog number sc-1584] 
Goat polyclonal anti-HPV16 E6 (C-19) [catalog number sc-1583] 
Goat polyclonal anti-Scribble (C-20) [catalog number sc-11049] 
 
Sigma Aldrich 
Rabbit polyclonal anti-WWTR1 (TAZ) [catalog number HPA007415] 
Mouse monoclonal anti-FLAG M2 [catalog number F3165] 
Mouse monoclonal anti-β-actin [catalog number A5441] 
Mouse monoclonal anti-6his [catalog number H1029] 
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Active Motif 
Rabbit polyclonal anti-p53 [catalog number 61657] 
 
GenScript 
Mouse monoclonal anti-GST HRP-conjugated [catalog number A00866] 
 
QED Bioscience 
Rabbit polyclonal anti-6his HRP-conjugated [catalog number 18814P] 
 
3.1.7.2 Secondary antibodies. 
 
Santa Cruz Biotechnology 
Goat anti-mouse HRP-conjugated [catalog number sc-2055] 
Goat anti-rabbit HRP-conjugated [catalog number sc-2054] 
 
Millipore 
Rabbit anti-goat HRP-conjugated [catalog number AP106P] 
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3.2 Methods. 
 
3.2.1 Molecular Biology techniques. 
 
3.2.1.1 PCR amplification. 
 
For cloning purposes, genes on interest were amplified with the appropriate primers listed in 
Tables 3.1 and 3.2 through a standard PCR technique. Genes were amplified using Taq Gold 
DNA polymerase (Perkin Elmer). 
 
3.2.1.2 Enzymatic restriction. 
 
For ligase-dependent cloning, PCR products and relative plasmids were digested with the 
appropriate restriction enzymes (NE BioLabs) for 4-6 hours at 37°C. 
 
3.2.1.3 DNA purification. 
 
Digested DNA products were subjected to electrophoresis on 0.8-1.5% agarose gels. Bands 
of interest were cut and purified either using Wizard® SV Gel and PCR Clean-Up System 
(Promega) or through a standard phenol-chloroform protocol for DNA purification, and 
subsequently concentrated using ethanol precipitation. 
 
3.2.1.4 Ligase-dependent cloning. 
 
Complementary DNA products were ligated after DNA purification using T4 DNA Ligase (NE 
BioLabs) overnight at 16°C. Competent E. coli DHϱα ǁeƌe theŶ tƌaŶsfoƌŵed ǁith ligatioŶ 
products and plated on LB-plates with the appropriate antibiotic. Colonies were screened 
and ligated plasmids were subjected to DNA sequencing. 
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3.2.1.5 Gateway® Technology. 
 
The Gateway® cloning system allows the highly efficient introduction of DNA sequences into 
appropriate vectors through site-specific recombination in a ligase-independent manner. 
The technology takes advantage of the recombination properties of the bacteriophage 
lambda. Genes of interest were amplified using appropriate primers listed in Table 3.2, 
bearing attB recombination sites on the flanking regions. DNA products were then purified 
as previously described and inserted within entry vectors using BP Clonase (Invitrogen) 
overnight at 25°C, according to manufacturer͛s protocol. Competent E. coli DHϱα ǁeƌe theŶ 
transformed with recombination products and plated on LB plates with the appropriate 
antibiotic. Colonies were screened and plasmids were subjected to DNA sequencing. Genes 
of interest were then moved from entry vectors to destination vectors using LR Clonase 
(Invitrogen) overnight at 25°C, according to manufacturer protocol. Successive steps were 
the same as previously described. 
 
3.2.1.6 Site-directed mutagenesis. 
 
The site-directed point mutagenesis was performed taking advantage of the QuikChange® 
Site-Directed mutagenesis system (Stratagene). Point mutations were introduced with 
specific primers listed in Table 3.3 and mutated plasmids were generated using Pfu Turbo 
DNA polymerase (Agilent Technologies), according to manufacturer͛s protocol. PCR products 
were then digested with DpnI restriction enzyme for 2 hours at 37°C in order to remove 
parental DNA. Competent E. coli DHϱα ǁeƌe theŶ tƌaŶsfoƌŵed ǁith amplification products 
and plated on LB-plates with the appropriate antibiotic. Colonies were then screened and 
mutated plasmids were subjected to DNA sequencing. 
 
3.2.1.7 DNA sequencing. 
 
Recombinant and mutated plasmids were analysed with Sanger sequencing using BigDye 
Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) containing fluorescent labelled 
dideoxynucleotide terminators (ddNTPs). Reactions and PCR conditions were set according 
to the manufacturer͛s protocol, and performed using sequencing primers listed in Table 3.4. 
Amplification products were purified by a standard ethanol precipitation procedure and 
examined by capillary electrophoresis on an ABI Prism 3130xl (Applied Biosystems). 
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3.2.2 Recombinant plasmid construction. 
 
Plasmid pcDNA-Xpress-His-USP15 was purchased from Addgene Inc. (Cambridge, MA, USA). 
Plasmids p513-HPV16 E6, E6 F47R, E6 6C/6S and plasmid pcDNA3-E6AP were a kind gift of 
Prof. Lawrence Banks (ICGEB, Trieste, Italy).  
Plasmid pCS2+ HA-p53, containing wild-type human TP53 gene with an N-terminal nine-
residue tag of hemagglutinin (HA), was a kind gift of Prof. Michelangelo Cordenonsi 
(Department of Molecular Medicine, Padua, Italy).  
Plasmids pcDNA3-RLuc and pcDNA3-RLuc-UL44 were a kind gift of Dr. Gualtiero Alvisi 
(Department of Molecular Medicine, Padua, Italy). 
For Bioluminescence Resonance Energy Transfer assays, plasmid p513-HPV16 E6 6C/6S was 
preliminarily reverted into the non-aggregating wild-type-like mutant E6 4C/4S as previously 
described [Zanier et al., 2012] using the QuikChange® Site-Directed mutagenesis system 
(Stratagene). HPV16 E6 DNA sequences (E6 wild-type, E6 4C/4S and E6 N-terminal domain, 
E6N amino acids 1-80) were then PCR amplified from the respective p513 plasmid using 
specific primers for Gateway® cloning system. Forward primers contained the attB1 
recombinant site while complementary reverse primers contained the attB2 recombinant 
site with or without a TAA stop codon. Purified PCR products were cloned into a Gateway® 
entry vector (pDONR207) using BP Clonase (Invitrogen). Sequence-verified clones were used 
to transfer E6 sequences into Gateway® destination vectors (pDEST, pcDNA3, and pT-REX) 
using LR Clonase (Invitrogen). Final constructs consisted of E6, E6 4C/4S and E6N with either 
N-terminal or C-terminal YFP, and with either N-terminal or C-terminal RLuc. Additionally, 
plasmid expressing FLAG-E6N was also constructed for BRET competition assays. 
Recombinant plasmids were then mutagenized to create splicing-defective mutants as 
previously described [Pim et al., 2009] and to create dimerization-defective mutants (F47R 
and F47R/Y43E) using the QuikChange® Site-Directed mutagenesis system (Stratagene) as 
described in Paragraph 3.2.1.6.  
For the production of recombinant p53 constructs, wild-type human p53 was PCR amplified 
from pCS2+ HA-p53 plasmid using specific primers for Gateway® cloning system. Cloning 
strategy was the same as described above. Final constructs consisted of wild-type p53 with 
either N-terminal or C-terminal RLuc. 
For in vitro protein expression and purification, E6 4C/4S and E6N sequences were PCR 
amplified from the respective p513 plasmid and cloned into pET28a+ and pDEST15 vectors in 
order to produce 6his-tagged and GST-tagged proteins, respectively. E6 sequences were 
ligated downstream of the 6his and GST sequences, between EcoRI and NotI sites of 
pET28a+ plasmid, and between XhoI and MluI sites of pDEST15 plasmid, respectively. 
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3.2.3 Cell culture and transient transfection techniques. 
 
All cells were grown at 37°C, 5% CO2, iŶ DulďeĐĐo͛s ŵodified Eagle͛s ŵediuŵ ;DMEM, Life 
Technologies, Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS) 
and 1% penicillin/streptomycin (pen/strep), except for CaSki cells, that were cultivated in 
Roswell Park Memorial Institute medium (RPMI, Life Technologies, Thermo Fisher Scientific) 
supplemented as described above. 
In order to optimize recombinant protein expression through transient transfections, HEK 
293T, C33A and H1299 cells were preliminarily subjected to test experiments using different 
transfection reagents, as a mean to determine the best transfection reagent to be used for 
further experiments. Cells were plated on 24-well plates and transfected with 2.5 μg of 
pDEST-YFP-E6 vector using Lipofectamine2000® (Thermo Fisher Scientific), ExGen500® 
(Biomol GmbH), Arrest-In™ ;OpeŶ BiosǇsteŵsͿ or CaPO4 as follows: 
 Lipofectamine2000®: transfections were carried out in DMEM with a Lipofectamine-
DNA ƌatio of Ϯ:ϭ ;μl/μgͿ, aĐĐoƌdiŶg to ŵaŶufaĐtuƌeƌ͛s pƌotoĐol. TƌaŶsfeĐtioŶ ŵiǆtuƌes 
were then distributed dropwise over the culture medium and then replaced with 
complete DMEM after 6 hours.  
 ExGen500®: transfections were carried out in 150 mM NaCl with an ExGen-DNA ratio 
of ϯ.ϯ:ϭ ;μl/μgͿ, aĐĐoƌdiŶg to ŵaŶufaĐtuƌeƌ͛s pƌotoĐol. TƌaŶsfeĐtioŶ ŵiǆtuƌes 
represented 1/10 of the total volume of the culture medium and were distributed 
dropwise over the cells, then replaced with complete medium after 6 hours. 
 Arrest-In™: transfections were carried out in DMEM with an Arrest-In:DNA ratio of 
ϱ:ϭ ;μl/μgͿ, aĐĐoƌdiŶg to ŵaŶufaĐtuƌeƌ͛s pƌotoĐol. Cultuƌe ŵediuŵ ǁas ƌeŵoǀed aŶd 
the transfection mixtures were gently added to the cells. After 6 hours, transfection 
medium was replaced with complete DMEM. 
 CaPO4: transfections were carried out in ddH2O containing HEPES Buffered Saline 1x 
;HB“, Ϯϱ ŵM HEPE“, ϭϰϬ ŵM NaCl, ϳϱϬ μM Na2HPO4) and 125 mM CaCl2 for the 
production of CaPO4-DNA crystals. Transfection mixtures were then distributed 
dropwise over the culture medium and then replaced with complete DMEM after 6 
hours. 
At 24 hours post-transfection, cells were collected, washed twice with Phosphate Buffered 
Saline 1x ;PB“Ϳ, ƌesuspeŶded iŶ ϭϬϬ μl PB“ aŶd tƌaŶsfeƌƌed iŶto a ďlaĐk ϵϲ-well OptiPlates 
(Costar) for fluorimetric analysis. Cells were exposed at an excitation wavelength of 485 ± 15 
nm, measuring YFP emission at 535 ± 25 nm, integrated over 1 s, using a VICTOR X2 
Multilabel Plate Reader (PerkinElmer). 
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For silencing of E6/E7 protein expression in HPV-positive cell lines, SiHa, CaSki and Hela cells 
were plated at 30% confluence and transfected with anti-E6/E7 siRNAs with Lipofectamine 
RNAiMax (Thermo Fisher ScientifiĐͿ aĐĐoƌdiŶg to ŵaŶufaĐtuƌeƌ͛s pƌotoĐol. Cells ǁeƌe theŶ 
harvested and plated for proliferation assays described in Paragraph 3.2.12. 
 
 
3.2.4 Bioluminescence Resonance Energy Transfer (BRET) assays. 
 
In order to detect the homodimerization of HPV16 E6 in living cells, 105 or 2x105 HEK 293T 
cells were seeded on 24-well plates and transfected with 500 ng of YFP-tagged constructs to 
test localization and expression levels, by detecting the fluorescent signal as described 
below. To maximize protein expression levels, subsequent experiments were carried out 
cotransfecting 500 ng of USP15. Appropriate amounts of each RLuc-tagged construct were 
selected to yield a luminometric signal of about 2000 ± 500 luminescence units (LU) at 5 
minutes after substrate addition as described below. RLuc-tagged constructs were then 
transfected alone or in combination with YFP-tagged fusion proteins to calculate BRET values 
as described below. Transfections of recombinant full-length E6 4C/4S proteins were 
normalized using p513-E6 plasmid instead of empty vector, and transfected cells were 
treated with proteasome inhibitor MG-132 (Z-Leu-Leu-Leu-al, Sigma-Aldrich) at a final 
ĐoŶĐeŶtƌatioŶ of ϰϬ μM foƌ ϯ houƌs ďefoƌe haƌǀestiŶg. As a Ŷegatiǀe ĐoŶtƌol, ‘LuĐ-UL44 was 
cotransfected with YFP-E6 4C/4S in the presence of 500 ng of USP15. Data were collected at 
24 hours post-transfection as described below. 
For BRET saturation assays, 105 HEK 293T cells were seeded on 24-well plates and fixed 
amounts of RLuc-E6N, RLuc-E6N F47R and RLuc-E6N F47R/Y43E were cotransfected with 500 
ng of USP15 in the presence of increasing quantities of the relative YFP-tagged protein or 
empty vector. As a negative control, plasmid pcDNA-RLuc was cotransfected with 500 ng of 
USP15 in the presence of increasing quantities of YFP-E6N or empty vector. Data were 
collected at 48 hours post-transfection as described below. 
For BRET competition assays, 2x105 HEK 293T cells were seeded on 24-well plates and 
transfected with RLuc-E6 4C/4S and YFP-E6 4C/4S as previously described, in the presence of 
exogenous p53 and E6AP or empty vector. As a positive control, recombinant full-length E6 
4C/4S constructs were cotransfected with FLAG-E6N. Data were collected at 24 hours post-
transfection after treatment with proteasome inhibitor MG-132 as previously described. 
Cells were then harvested and stored at -80°C for western blot analysis. 
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To determine the interaction between HPV16 E6 and p53 in living cells, 105 HEK 293T cells 
were seeded on 24-well plates and transfected with RLuc-p53 in the presence of YFP-E6 
4C/4S, YFP-E6 4C/4S F47R, YFP-E6 4C/4S F47R/Y43E or empty vector. All transfections were 
performed including 500 ng of USP15. As a negative control, RLuc-p53 was cotransfected 
with YFP-E6N. At 3 hours before harvesting, cells were treated with MG-132. At 24 hours 
post-transfection data were collected as described below. 
All transfections were performed using Lipofectamine2000® (Thermo Fisher Scientific) as 
described in Paragraph 3.2.3. 
 
 
3.2.5 BRET data analysis. 
 
At 24 or 48 hours post-tƌaŶsfeĐtioŶ, HEK ϮϵϯT Đells ǁeƌe ǁashed aŶd ƌesuspeŶded iŶ ϮϵϬ μl 
PB“. Cells ǁeƌe tƌaŶsfeƌƌed iŶ tƌipliĐate ;ϵϬ μl peƌ ǁellͿ iŶto black 96-well OptiPlates (Costar) 
for fluorimetric/luminometric analysis. Fluorimetric analysis was performed exposing cells at 
an excitation wavelength of 485 ± 15 nm, measuring YFP-tagged proteins emission at 535 ± 
25 nm (Emfluo535), integrated over 1 s, using a VICTOR X2 Multilabel Plate Reader 
;PeƌkiŶElŵeƌͿ. LuŵiŶoŵetƌiĐ aŶalǇsis ǁas peƌfoƌŵed addiŶg ϭϬ μl/ǁell of benzyl-
ĐoeleŶteƌaziŶe ϱϬ μM ;P.j.k. GŵďHͿ ŵeasuƌiŶg the eŵissioŶ sigŶals at ϱϯϱ ± Ϯϱ Ŷŵ 
(Emlum535) and 460 ± 25 nm (Emlum460), integrated over 1 s, at 5 and 15 minutes after 
substrate addition. BRET values (BV) were calculated for each well, after blank substraction, 
as Emlum535/Emlum460. BRET ratios (mBR) were calculated for cells cotransfected with YFP- 
and RLuc- tagged constructs as (BVsample - BVbackground)x1000 at 15 minutes after substrate 
addition, where BVbackground represents the Emlum460 of cells transfected with the relative 
RLuc-tagged construct alone. For BRET saturation experiments, mBRs were plotted against 
Y/R values, expressed as Emfluo535/Emlum460 calculated at 5 minutes after substrate 
addition. 
 
 
3.2.6 Microscopy. 
 
At 24 hours post-transfection, HEK 293T cells transfected with YFP-tagged constructs were 
observed with an inverted Leica DM IL LED microscope, with a 40X objective, at an excitation 
wavelength of 488 nm. 
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3.2.7 Cell-based p53 degradation assay. 
 
To monitor the E6-mediated degradation of p53 in HPV-negative cell lines, 6x105 C33A 
cells/well or 3x105 HEK 293T cells/well were seeded on 6-well plates and transfected with 5 
μg of spliĐiŶg-defective p513-E6, p513-E6 F47R, p513-E6 F47R/Y43E or empty vector using 
CaPO4 and Lipofectamine2000® (Thermo Fisher Scientific), respectively. Cells were grown in 
complete medium at 37°C for 48 hours before harvesting. 
For small molecule testing, selected compounds were diluted in complete medium and 
added to C33A cells after the 6 hour-incubation time of the transfection protocol (see also 
Paragraph 3.2.3). Cells were then treated for 48 hours before harvesting.  
To monitor the compound 12-induced proteasome-dependent degradation of E6, C33A cells 
were transfected and treated as previously described. At 3 hours before harvesting, 
proteasome inhibitor MG-ϭϯϮ ;“igŵa AldƌiĐhͿ ǁas added at a fiŶal ĐoŶĐeŶtƌatioŶ of ϰϬ μM iŶ 
the presence of fresh compound 12. 
 
 
3.2.8 Cell-based assay for TAZ induction. 
 
To monitor the E6-mediated induction of TAZ in HPV-negative cell lines, 6x105 C33A 
cells/well were seeded on 6-ǁell plates aŶd tƌaŶsfeĐted ǁith ϭ μg of spliĐiŶg-defective p513-
E6, p513-E6 F47R, p513-E6 F47R/Y43E or empty vector using CaPO4. Similarly, 2.5x105 H1299 
cells weƌe tƌaŶsfeĐted ǁith Ϭ.ϱ μg of pϱϭϯ-E6, p513-E6 F47R, p513-E6 F47R/Y43E or empty 
vector using Arrest-IŶ™ ;OpeŶ BiosǇsteŵsͿ. Cells ǁeƌe gƌoǁŶ at ϯϳ°C iŶ seƌuŵ-reduced 
medium (DMEM, 1% FBS, 1% pen/strep) in order to enhance Hippo downregulation as 
previously described [He et al., 2015]. Cells were harvested when they reached confluence 
at 48 and 24 hours post-transfection, respectively. 
 
 
63 
 
3.2.9 Western Blot. 
 
3.2.9.1 Protein extraction and quantification. 
 
Adherent HEK 293T and H1299 cells were trypsinized and harvested, whereas floating C33A 
cells were also collected before trypsinization of adherent cells. Cells were pelleted at 100 x 
g for 5 minutes at 4°C and frozen at -80°C. Pellets were then thawed, resuspended in RIPA 
buffer (50 mM Tris, 150 mM NaCl, 1% NP-40, 0.1% SDS) with Halt Protease Inhibitor Cocktail 
1x (Thermo Fisher Scientific) and incubated on ice for 30 minutes to let the lysis occur. 
Samples were then centrifuged at 15000 rpm for 15 minutes at 4°C to remove cellular 
debris. Protein supernataŶts ǁeƌe ĐolleĐted aŶd ƋuaŶtified usiŶg PieƌĐe™ BCA PƌoteiŶ AssaǇ 
Kit (Thermo Fisher Scientific) on 96-ǁell plates, aĐĐoƌdiŶg to ŵaŶufaĐtuƌeƌ͛s pƌotoĐol. IŶ this 
way, protein concentrations are determined through the reduction of Cu2+ to Cu+ by proteins 
in an alkaline medium, with the selective colorimetric detection of the Cu+ cations through 
the use of the bicinchoninic acid (BCA) contained in the working reagent. Absorbance values 
were read at 620 nm on a spectrophotometer microplate reader (Tecan Sunrise). 
 
3.2.9.2 SDS-PAGE and protein transfer. 
 
Cellular proteins were separated according to their molecular weight through sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGEͿ ďǇ loadiŶg ϱϬ μg of Đellulaƌ 
lysates on 8-12% SDS-PAGE gels, depending on the size of the protein to be visualized. 
Samples were mixed with Loading buffer 5x (312.5 mM Tris-HCl , 50% glycerol, 10% SDS, 5% 
β-mercaptoethanol, 0.5% bromophenol blue, pH 6.8) and boiled for 5 minutes prior to 
loading. Electrophoretic runs were performed at 80 V for about 3 hours in Running buffer 
(25 mM Tris, 192 mM glycin, 0.1% SDS) with Prestained Protein Sharpmass V marker 
(Euroclone). Proteins were then transferred to polyvinylidene difluoride (PVDF) membranes, 
previously activated in 100% methanol for 30 seconds, in a wet transfer apparatus (BioRad) 
at 350 mA, for 1 hour on ice, in Transfer buffer (25 mM Tris, 192 mM glycin, 20% methanol, 
0.03% SDS). Gels and membranes were equilibrated in Transfer buffer before the 
electrophoretic run. For transferring high molecular weight proteins (approximately >150 
KDa), cellular lysates were loaded on 7.5% SDS-PAGE gels and proteins were separated as 
previously described. Proteins were then transferred on PVDF membranes overnight at 30 V 
in cold room. Following transfer, PVDF membranes were incubated in blocking solution, 
TBST-5% milk (Tris Buffered Saline 1x, TBS, 0.1% Tween20, 5% milk) for 2 hours at room 
temperature (RT) and subsequently incubated overnight with the primary antibodies on a 
platform shaker. Membranes were then washed 4 times on agitation with TBST (15 minutes 
per wash), incubated with the relative horseradish peroxidase (HRP)-conjugated secondary 
antibodies for 1 hour at RT on agitation, and washed 4 times with TBST as before.  
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3.2.9.3 Detection of blotted proteins. 
 
Protein bands were detected through the HRP-dependent activation of a chemoluminescent 
substrate, using either a VersaDoc imager (BioRad) or BioMax X-ray films (Kodak) with 
LiteAblot EXTEND (Euroclone) and ECL (GE Healthcare) substrates, respectively. For the 
detection of blotted proteins, primary antibodies were used as follows: anti-p53 1:5000 in 
TBST-5% milk; anti-β-actin 1:8000 in TBST-5% milk; anti-WWTR1 (TAZ) 1:1000 in TBST-0.5% 
milk; anti-Scribble 1:500 in TBST-0.5% milk; anti-FLAG 1:2000 in TBST-5% milk. Wild-type E6 
was detected using anti-HPV16 E6 (N-17) 1:500 in TBST-0.1% milk. However, for the 
simultaneous detection of wild-type and mutant E6, anti-HPV16 E6 (C-19) was used, 1:200 in 
TBST-0.1% milk. For GST pull-down assays, monoclonal anti-6his was used 1:10000 in TBST-
5% milk. Secondary antibodies were all used 1:2000 in TBST-5% milk. For a detailed list, see 
also Paragraph 3.1.7. 
 
3.2.9.4 Stripping and reprobing. 
 
For the reprobing of blotted membranes, stripping was performed by immersing the 
membranes into Stripping buffer (62.5 mM Tris-HCl, Ϯ% “D“, Ϭ.ϴ% β-mercaptoethanol, pH 
6.8), with a 30-minute incubation at 50°C. Membranes were then extensively washed with 
TBS, re-blocked with TBST-5% milk and incubated overnight with the primary antibody as 
previously described. 
 
 
3.2.10 Cell growth curves. 
 
In order to determine the proper number of cells to be plated on 96-well plates for 
compound testing, cell growth curves were determined by plating different amounts of SiHa, 
CaSki, Hela, C33A and HFF cells on 96-well plates, ranging from 103 to 105 cells/well. 
Following cell adhesion, compound treatment was simulated simply by growing cells at 37°C 
for 24 or 48 hours. Cell confluence was determined by means of the relative cell viability 
through the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) method. 
Cells ǁeƌe iŶĐuďated ǁith ϭϬ μl/ǁell of MTT suďstƌate ;“igŵa AldƌiĐhͿ, pƌeǀiouslǇ dissolǀed 
in PBS (5 mg/ml), for 4 hours at 37°C to allow the incorporation and the reduction of the 
tetƌazoliuŵ salt. Cells ǁeƌe theŶ lǇsed ǁith ϭϬϬ μl/ǁell of “oluďiliziŶg solutioŶ ;ϭϬ% “D“, 
0.01 N HCl) overnight at 37°C. Absorbances were read at 620 nm on a spectrophotometer 
microplate reader (Tecan Sunrise). 
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3.2.11 Cytotoxicity assays. 
 
2x104 SiHa, 1.5x104 CaSki, 5x103 Hela, 5x104 C33A and 104 HFF cells were seeded on 96-well 
plates 24 hours prior to drug addition. Increasing concentrations of test compounds were 
added on cells in complete fresh medium (DMEM, 10% FBS, 1% pen/strep) for 48 hours. The 
cytotoxicities were assayed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) method as described in Chapter 3.2.10. 
 
 
3.2.12 Proliferation assays. 
 
3.2.12.1 Colony formation assay. 
 
To evaluate cell proliferation on plastic surface after compound treatment, SiHa, CaSki, Hela 
and C33A cells were seeded in duplicate on 6-well plates 24 hours prior to drug addition at a 
density of 5x102, 2.5x102, 102 and 1.5x102 cells/well, respectively. Cells were then treated 
tǁiĐe a ǁeek ǁith ĐoŵpouŶds ϯ aŶd ϲ at ϱϬ aŶd ϭϬϬ μM aŶd ǁith ĐoŵpouŶd ϭϮ at ϮϬ aŶd 
ϱϬ μM, ƌespeĐtiǀelǇ, iŶ Đoŵplete fƌesh ŵediuŵ foƌ tǁo ǁeeks, uŶtil ĐoloŶies haǀe foƌŵed iŶ 
the control samples, where the cells were treated with 0.1% DMSO in complete fresh 
medium. Cells were then fixed and stained with crystal violet using a Fixing/Staining solution 
(0.05% crystal violet, 1% formaldehyde, 1% methanol in PBS) for 20 minutes at RT, then 
washed with water and air dried. Colonies were counted by visual inspection and aggregates 
with > 50 cells were scored as colonies. 
 
3.2.12.2 Soft agar colony formation assay. 
 
To evaluate the anchorage-independent growth of cells after compound treatment, 104 
SiHa, CaSki and Hela cells were plated in duplicate on 6-well plates 24 hours prior to drug 
addition in complete growth medium containing 0.3% low melting agarose (Invitrogen), over 
a 0.6% low melting agarose layer without cells. SiHa and CaSki cells were treated for 8 weeks 
while Hela cells were treated for 3 weeks as described in Paragraph 3.2.12.1 until colonies 
have formed in the control samples. Cells were then fixed in 4% paraformaldehyde (PFA) in 
PBS for 20 minutes at RT and observed under phase-contrast microscopy. Aggregates with > 
50 cells were scored as colonies and counted. 
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3.2.13 Protein expression and purification. 
 
3.2.13.1 Test expression experiments. 
 
Before large-scale protein expressions, the expression level and solubility of 6his-E6 4C/4S, 
GST-E6 4C/4S, 6his-E6N and GST-E6N proteins were determined by the visual estimation of 
the intensity of the corresponding band on SDS-PAGE gels after small scale test expressions. 
To test the yield of recombinant protein production, competent Escherichia coli strain 
BL21(DE3)pLysS was transformed with plasmids pDEST15-E6N, pDEST15-E6 4C/4S, pET28a-
E6N or pET28a-E6 4C/4S and grown at 37°C in 100 ml LB medium containing the appropriate 
antibiotic until the OD600 was 0.8. Protein expressions were induced either for 4 hours at 
37°C or overnight at 16°C, by the addition of 0.5 mM isopropyl-β-D-thiogalactopyranoside 
(IPTG). Expression results were checked on 8-15% SDS-PAGE gels stained with Coomassie 
solution (40% methanol, 10% acetic acid, 0.05% (wt/vol) Coomassie Brilliant Blue) for 1 hour 
at RT and destained with Destaining solution (40% methanol, 10% acetic acid) until the 
background returned clear. 
To test the solubility of the recombinant proteins, expressions were induced both at 37°C or 
at 16°C as described above. Cells were then pelleted, resuspended in PBS with 1 mg/ml 
lysozyme and complete protease inhibitors (Roche Molecular Biochemicals) and lysed by two 
freeze/thaw cycles. Bacterial lysates were then centrifuged at 13000 x g for 3 minutes, 
supernatants were collected while pellets were resuspended in PBS. Expression results were 
checked on 8-15% SDS-PAGE gels as described above. 
 
3.2.13.2 Protein expression and purification. 
 
Competent Escherichia coli strain BL21(DE3)pLysS was transformed with plasmids pDEST15-
E6N or pET28a-E6N to express recombinant GST-E6N or 6his-E6N proteins, respectively. Cells 
were grown at 37°C in LB medium containing the appropriate antibiotic until the OD600 was 
0.8 and protein expressions were induced by the addition of 0.5 mM IPTG overnight at 16°C. 
For GST-E6N protein purification, cells were pelleted, resuspended on ice in Resuspension 
buffer (20 mM Tris-HCl, 100 mM NaCl, 10 mM DTT, 0.2 mM EDTA, pH 7.5) with 1 mg/ml 
lysozyme and complete protease inhibitors (Roche Molecular Biochemicals) and lysed by two 
freeze/thaw cycles and by sonication. Bacterial lysate was centrifuged at 16000 x g for 30 
minutes at 4°C, supernatant was collected, centrifuged again at 16000 x g for 10 minutes at 
4°C and applied to Glutathione Sepharose 4Fast Flow resin (GE Healthcare) packed on a 
Glass Econo-Column (BioRad) equilibrated in Resuspension buffer.  
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Bound protein was extensively washed with Resuspension buffer and eluted with Elution 
buffer (20 mM Tris-HCl, 100 mM NaCl, 10 mM DTT, 20 mM glutathione, pH 8). 
For untagged E6N protein purification, GST-E6N protein bound to GSH-resin was extensively 
washed with Resuspension buffer, equilibrated in Cleavage buffer (50 mM Tris-HCl, 150 mM 
NaCl, 1 mM DTT, 1 mM EDTA, pH 7.5) and incubated with 1 ml of PreScission Protease (GE 
Healthcare) 1:10 in cleavage buffer for 4 hours at 4°C. The untagged E6N protein was then 
eluted with Cleavage buffer. 
For 6his-E6N protein purification, cells were pelleted, resuspended on ice in Resuspension 
buffer (20 mM Tris-HCl, ϱϬϬ ŵM NaCl, ϭϬ ŵM β-mercaptoethanol, 25 mM imidazole, pH 7.5) 
with 1 mg/ml lysozyme and protease inhibitors, lysed and pelleted as described above. 
Lysate was applied to a 1 ml HisTrap FF column (GE Healthcare) equilibrated with 
Resuspension buffer using an Äkta Purifier apparatus (GE Healthcare). Bound protein was 
extensively washed with Resuspension buffer and then eluted with Elution buffer (20 mM 
Tris-HCl, ϱϬϬ ŵM NaCl, ϭϬ ŵM β-mercaptoethanol, 250 mM imidazole, pH 7.5). 
Purified proteins (GST-E6N, 6his-E6N and untagged E6N) were dialyzed at 4°C against Storage 
buffer (20 mM Tris-HCl, 150 mM NaCl, 5 mM DTT, 30% (vol/vol) glycerol, pH 7) in slow 
agitation using either Dialysis tubing cellulose membranes (Sigma Aldrich) or Slide-A-Lyzer 
dialysis cassettes (Thermo Fisher Scientific) and then stored at -80°C. Purification results 
were checked onto 12-15% SDS-PAGE gels as previously described. 
 
3.2.13.3 Protein quantification. 
 
Purified proteins were quantified using the Bio-Rad Protein Assay kit (BioRad) on 96-well 
plates, aĐĐoƌdiŶg to ŵaŶufaĐtuƌeƌ͛s pƌotoĐol. QuaŶtifiĐatioŶ is ďased oŶ the ŵethod of 
Bradford, through which the concentration of soluble proteins is determined by means of 
the color change of the Coomassie Brilliant Blue dye. Absorbance values were read at 620 
nm on a spectrophotometer microplate reader (Tecan Sunrise). 
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3.2.14 GST pull-down assay. 
 
E6N self-association was preliminary assayed through a GST pull-down. Purified recombinant 
GST or GST-E6N were incubated with Glutathione Sepharose 4Fast Flow agarose beads (GE 
Healthcare) in Binding buffer (2.5 mM HEPES, 12.5 mM MgCl2, 20% glycerol, 0.1% NP-40, 150 
mM KCl, 0.015% (wt/vol) BSA, 1 mM DTT, pH 7.5) in the presence of 6his-E6N. Binding 
reactions were performed either at 4°C or RT for 2 hours in slow agitation with a 6his-
E6N:GST-E6N ratio of 4:1 (nmol/nmol). Samples were then loaded and packed on Poly-Prep 
columns (BioRad), washed 5 times with TNEN buffer (20 mM Tris-HCl, 100 mM NaCl, 0.5 mM 
EDTA, 0.25% NP-40, pH 8) and bound proteins were eluted with Elution buffer (20 mM Tris-
HCl, 100 mM NaCl, 0.5 mM EDTA, 0.25% NP-40, 20 mM glutathione, pH 8). Samples were 
then loaded on a 15% SDS-PAGE gel and analyzed through western blotting as described in 
Paragraph 3.2.9. 
 
 
3.2.15 ELISA E6N homodimerization assay. 
 
In preliminary experiments, 96-well microtiter plates (Nuova Aptaca) were coated with 400 
ng of GST-E6N or 6his-E6N in PBS for 3 hours at 37°C and blocked with 2% (wt/vol) BSA (Sigma 
Aldrich) in PBS for 2 hours at 37°C. Wells were washed with PBST (PBS, 0.3% Tween20) and 
those coated with GST-E6N were incubated overnight with increasing quantities of 6his-E6N 
or 6his-PA239-716, while wells coated with 6his-E6N were incubated with increasing quantities 
of GST-E6N or GST, in PBS at RT. Wells were then washed with PBST and incubated for 1 hour 
at RT with HRP-conjugated anti-6his antibody (QED Bioscience, 1:10000 in PBS with 2% 
(vol/vol) FBS) and HRP-conjugated anti-GST antibody (GenScript, 1:5000 in PBS with 2% 
(vol/vol) FBS), respectively. Wells were washed again with PBST, incubated with the 
ĐhƌoŵogeŶiĐ suďstƌate ϯ,ϯ′,ϱ,ϱ′tetƌaŵethǇlďeŶzidiŶe ;TMB, KPL IŶĐ.Ϳ aŶd aĐidified with HCl 
3.6%. Absorbances were read at 450 nm on a spectrophotometer microplate reader (Tecan 
Sunrise). 
For preliminary competition assays, wells were coated with 400 ng of 6his-E6N as described 
before, and incubated overnight with 400 ng of GST-E6N in the absence or presence of 
increasing amounts of purified 6his-E6N. Samples were washed, incubated with the HRP-
conjugated anti-GST antibody (GenScript) and processed as previously described.  
To evaluate the aspecific interaction between E6N and GST, 96-well microtiter plates (Nuova 
Aptaca) were coated with 400 ng of GST as described above and incubated overnight with 
increasing amounts of 6his-E6N in the absence or presence of increasing amounts of GST-
E6N. Interaction signals were detected using the HRP-conjugated anti-6his antibody (QED 
Bioscience) as previously described. 
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For the detection of E6N homodimerization and to subsequently test the ability of candidate 
compounds to inhibit E6N self-association, 96-well microtiter plates (Nuova Aptaca) were 
coated with 400 ng of untagged E6N in PBS for 3 hours at 37°C and blocked as previously 
described. Coated wells were washed with PBST and, for interaction assays, incubated 
overnight with increasing quantities of 6his-E6N or 6his-PA239-716 in DMEM at 30°C while, for 
inhibition assays, incubated overnight with 400 ng of 6his-E6N in the absence or presence of 
increasing quantities of E6N, UL44 or test compounds in DMEM at 30°C. After washing with 
PBST, samples were incubated with HRP-conjugated anti-6his antibody (QED Bioscience) and 
processed as described above. 
 
 
3.2.16 Statistical analyses. 
 
Data were analyzed with unpaired Student t test or one-way analysis of variance (ANOVA) 
using GraphPad Prism 6 (GraphPad Software Inc.). Values were presented as Mean ± SD of at 
least two independent experiments. Statistical significance was calculated with a p value < 
0.05. Binding curves were calculated by non-linear regression of the data. 
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4. Results 
 
4.1 Biological studies on the homodimerization of HPV16 E6. 
 
4.1.1 HPV16 E6 can self-associate in living cells. 
 
To study the site-specific homodimerization of HPV16 E6 in living cells, the N-terminal 
domain of E6 (E6N) and full-length E6, bearing a substitution in the splicing donor site 
(G226A) which prevents the expression of the spliced isoforms, were preliminarily chosen 
for BRET assay. A panel of recombinant proteins bearing either YFP or Renilla Luciferase 
(RLuc) at the N-terminal or at the C-terminal end of each E6 sequence was produced. 
Recombinant constructs were transfected into HEK 293T cells, which are easily transfectable 
and allow high levels of exogenous protein production. Transfections were performed with 
Lipofectamine2000®, which was chosen because of the higher reproducibility observed in 
preliminary experiments, as compared to other transfection reagents (data not shown). 
Expression levels of YFP-tagged proteins were preliminarily evaluated by the means of the 
fluorescent emission signals at 535 nm. Notably, the constructs with the N-terminal YFP tag 
resulted to be more stable than the counterparts with the C-terminal YFP tag (data not 
shown). The latter were then excluded from the successive experiments, as BRET assays 
require high amounts of YFP-tagged proteins to saturate the interacting molecule carrying 
Renilla Luciferase. Subsequently, the localization of YFP recombinant proteins was detected 
in HEK 293T cells. The recombinant N-terminal domain was ubiquitously localized into the 
cell, while wild-type E6 localized predominantly into the nucleus as expected, thanks to the 
presence of all its three NLS sequences (Figure 4.1). However, overexpression of YFP-E6 
induced the formation of distinctive nuclear foci that resembled nuclear aggresomes, which 
were recently reported to occur as a result of E6 protein aggregation following its 
overexpression in transfected cells [Stutz et al., 2015]. Thus, to circumvent the possible 
drawbacks due to the E6-mediated aggregation of YFP-E6, we also constructed recombinant 
constructs using a splicing-defective, non-aggregating mutant isoform (E6 4C/4S), where four 
non-conserved cysteines on the protein surface are mutated into serines, without affecting 
protein functionality [Zanier et al., 2012]. Notably, recombinant E6 4C/4S localized mainly 
into the nucleus as expected but generally with no formation of the nuclear foci previously 
observed with the wild-type protein (Figure 4.1).  
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Figure 4.1. Cellular localization of YFP-tagged recombinant proteins. HEK 293T cells were 
transfected with YFP-E6N, YFP-E6 or YFP-E6 4C/4S and localization of recombinant constructs 
was visualized at 24 hours post-transfection. Fluorescent signals (upper panels) were merged 
with cell images visualized under phase-contrast microscopy (lower panels).  
 
To further increase the expression levels of YFP-tagged proteins, recombinant constructs 
were then cotransfected with the ubiquitin carboxyl-terminal hydrolase 15 (USP15), which 
was previously shown to stabilize E6 protein levels in cells [Vos et al., 2009]. In addition, in 
experiments with full-length E6, cells were also treated with the proteasome inhibitor MG-
132, in order to further enhance E6 protein stability. HEK 293T cells were then transfected 
with RLuc-tagged constructs in the presence of the relative YFP-tagged partner or empty 
vector, in order to detect the RLuc-dependent emission of YFP as a consequence of E6 self-
association. Notably, in preliminary experiments we observed different emissions of both 
RLuc-E6 and RLuc-E6 4C/4S in the absence or the presence of YFP-E6 and YFP-E6 4C/4S, 
respectively. Thus, we tested whether the global intracellular production of full-length E6 
may have an effect on the intracellular levels of E6 itself. Indeed, emission signals of RLuc-E6 
and RLuc-E6 4C/4S were drastically increased when the transfections were performed in the 
presence of untagged E6, instead of empty vector (Figure 4.2). This result agrees with 
previous data according to which HPV16 E6, and high-risk variants in general, are RNA-
binding proteins which can bind their own pre-mRNA, possibly enhancing their own 
translation [Bodaghi et al., 2009].  
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Figure 4.2. Different emission signals 
of RLuc-E6 and RLuc-E6 4C/4S. HEK 
293T cells were transfected with either 
RLuc-E6 or RLuc-E6 4C/4S in the 
presence of empty vector or untagged 
full-length E6. Emission signals were 
detected at 5 minutes after substrate 
addition and significantly increased 
luminescence signals were detected 
when recombinant full-length proteins 
were transfected in the presence of 
untagged E6 instead of empty vector. 
 
 
 
 
 
Thus, in order to detect the homodimerization of full-length E6, HEK 293T cells were 
transfected with RLuc-E6 or RLuc-E6 4C/4S in the presence of the relative YFP-tagged partner 
or untagged full-length E6. In these conditions, we could successfully detect the dimerization 
of both E6N and E6 4C/4S, with self-association signals of 155 ± 16 mBR and 103 ± 10 mBR, 
respectively. Interaction signals were significantly above the relative background of non-
specificity, where YFP-E6N and YFP E6 4C/4S were cotransfected with RLuc and RLuc-UL44, 
respectively (Figure 4.3). Unfortunately, we could not detect the homodimerization of wild-
type E6 in these experimental conditions, possibly because of the propensity of the wild-
type protein to aggregate upon ectopic overexpression.  
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Figure 4.3. Self-association signals of E6N and E6 4C/4S detected by BRET assay. HEK 293T 
cells were transfected with RLuc-E6N and RLuc-E6 4C/4S in the presence of YFP-E6N and YFP-
E6 4C/4S, respectively. Controls of non-specific interaction were obtained by transfecting 
HEK 293T cells with YFP-E6N and YFP-E6 4C/4S in the presence of an unfused or an unrelated 
protein, i.e., RLuc or RLuc-UL44, respectively. 
 
 
 
Strikingly, the introduction of point mutations in the predicted dimeric interface (F47R and 
F47R/Y43E) significantly reduced the self-association signals of both E6N and E6 4C/4S, 
confirming that E6 homodimerization is driven specifiĐallǇ ďǇ the αϮ-helix of the N-terminal 
domain (Figure 4.4). Subsequently, E6N, E6N F47R and E6N F47R/Y43E recombinant proteins 
were used to further study their self-association capacities in a BRET saturation assay, being 
the only constructs suitable for this kind of experiment. HEK 293T cells were transfected 
with increasing amounts of either wild-type or mutant YFP-tagged E6N in the presence of the 
relative RLuc-tagged protein, and binding curves were obtained. Indeed, mutant constructs 
exhibited a significative reduction of self-association, close to the background of non-
specificity, suggesting the effectiveness of these point mutations in disrupting the 
interaction (Figure 4.5). 
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Figure 4.4. Self-association signals of wild-type and dimerization-defective E6N and E6 
4C/4S mutants detected by BRET assay. HEK 293T cells were transfected with RLuc-tagged 
wild-type or dimerization-defective E6N and E6 4C/4S in the presence of the relative YFP-
tagged construct. Dimerization-defective mutants were obtained through a single or double 
point mutation (resulting in the amino acid substitutions F47R and F47R/Y43E, respectively) 
in the E6N and E6 4C/4S sequences.  
 
 
Figure 4.5. Binding curves of HPV16 E6N, E6N F47R and E6N F47R/Y43E obtained by BRET 
saturation assay. HEK 293T cells were transfected with RLuc-tagged E6N, E6N F47R and E6N 
F47R/Y43E in the presence of increasing amounts of the relative YFP-tagged protein. 
Dimerization-defective mutants showed a significantly reduced ability to self-associate, close 
to the background of non-specificity obtained by cotransfecting HEK 293T cells with RLuc 
and YFP-E6N. 
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4.1.2 HPV16 E6 directly dimerizes through its N-terminal domain. 
 
The detection of E6 self-association in living cells strongly suggested the occurrence of the 
homodimerization as a result of the direct interaction between two E6 monomers, as 
confirmed by the inability of the mutants to dimerize. However, the possibility that a third 
cellular binding partner may have induced the close contact of two E6 molecules in the BRET 
assay could not be ruled out. Thus, we sought to investigate the homodimerization of HPV16 
E6 also in vitro, as a way to determine the dependency of E6 self-association on the presence 
of other cellular proteins. We constructed recombinant vectors expressing both E6N and full-
length E6 4C/4S with N-terminal 6his or GST tags for purification purposes. Notably, we did 
not choose to express recombinant wild-type full-length E6 due to its known tendency to 
strongly aggregate and precipitate in vitro [Nominé et al., 2001; Zanier et al., 2007; Zanier et 
al., 2010]. Preliminarily, recombinant proteins were expressed in E. coli either at 37°C for 4 
hours or at 16°C overnight, in order to determine the culture conditions that could enhance 
recombinant protein production. Nevertheless, no significative differences were 
preliminarily observed between the two culture conditions (Figure 4.6).   
 
 
Figure 4.6. In vitro expression levels of recombinant (A) 6his-E6N, (B) GST-E6N, (C) 6his-E6 
4C/4S and (D) GST-E6 4C/4S. Protein expressions were induced either for 4 hours at 37°C 
(lanes 2) or overnight at 16°C (lanes 4). Expression levels were determined by means of the 
intensity of the relative band on SDS-PAGE gels.  
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Following these test expression studies, the intracellular solubility of the recombinant 
proteins was investigated by analyzing their presence in the insoluble or soluble cellular 
fraction. Notably, GST-E6N and 6his-E6N were found in both fractions while both GST-E6 
4C/4S and 6his-E6 4C/4S were found only in the insoluble fraction after cell lysis (Figure 4.7). 
Thus, recombinant full-length proteins were excluded from following purifications due to the 
difficulty in retrieving the proteins in the supernatant of cell lysates. Furthermore, we chose 
to perform subsequent expressions overnight at 16°C in order to minimize the possible 
temperature-dependent aggregation of the exogenous proteins expressed in E. coli. 
Recombinant GST-E6N and 6his-E6N proteins were then expressed and successfully purified 
from E. coli with one-step affinity purification on glutathione or nickel-charged resin, 
respectively. 
 
Figure 4.7. Solubility of recombinant proteins: (A) 6his-E6N, (B) GST-E6N, (C) 6his-E6 4C/4S 
and (D) GST-E6 4C/4S. Protein expressions were induced either for 4 hours at 37°C (lanes 1 
and 2) or overnight at 16°C (lanes 3 and 4). Supernatant and pellet samples were obtained 
through the separation of the soluble fraction from the insoluble fraction by centrifugation 
after cell lysis. The intracellular solubility of the recombinant proteins was determined by 
observing the presence of the relative band in the pellets (lanes 1 and 3) or supernatants 
(lanes 2 and 4) on SDS-PAGE gels. 
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To preliminarily assess the ability of GST-E6N and 6his-E6N to dimerize in vitro, we set-up a 
GST pull-down assay. Recombinant 6his-E6N was incubated with GST-E6N, or GST alone as a 
control, in the presence of glutathione resin. We then assessed the ability of GST-E6N to pull-
down the 6his-tagged protein after the elution step. Unfortunately, 6his-E6N was found only 
in the input fraction and was never detected in the elution samples, suggesting its inability to 
bind to GST-E6N in these experimental conditions (Figure 4.8). 
 
Figure 4.8. GST pull-down assay between 6his-E6N and GST-E6N shows the inability of the 
recombinant proteins to associate in these experimental conditions. Recombinant E6N 
proteins were incubated with glutathione agarose beads (input), loaded on columns, washed 
(wash) and eluted (elution). The binding between 6his-E6N and GST-E6N was determined by 
the presence of 6his-E6N in the elution samples, detected using a HRP-conjugated anti-6his 
antibody. 
 
Thus, we analyzed the self-association of E6N proteins through an ELISA-based in vitro assay 
by coating the wells of microtiter plates with either GST-E6N or 6his-E6N and then incubating 
with the relative partner of the coated protein. Preliminary experiments were conducted by 
coating microplate wells with 6his-E6N and then, after washes and blocking, incubating with 
increasing amounts of GST-E6N or GST as a control. Notably, we could detect a binding curve 
as a result of the association between the two recombinant E6N proteins, but unfortunately 
the background signal obtained with the GST control was considerably high (Figure 4.9). To 
test whether the detected association between 6his-E6N and GST-E6N was a result of a 
specific interaction, we performed an ELISA competition assay, by coating wells with 6his-
E6N and then incubating with GST-E6N in the presence of increasing amounts of the 
competitor 6his-E6N. Unexpectedly, the interaction signal increased instead of decreasing 
(Figure 4.10).  
79 
 
 
Figure 4.9. Preliminary ELISA-based assay for the detection of E6N self-association. 
Microtiter plates were coated with 6his-E6N and incubated with increasing amounts of GST-
E6N or GST as control. Bound proteins were detected by the use of a HRP-conjugated anti-
GST antibody. 
 
 
Figure 4.10. Preliminary ELISA-based competition assay. Microtiter plates were coated with 
6his-E6N and incubated with an equivalent amount of GST-E6N in the presence of increasing 
quantities of competitor 6his-E6N. GST-E6N bound to the coated 6his-E6N was detected by 
the use of a HRP-conjugated anti-GST antibody. Interaction signal increased instead of 
decreasing. 
 
Thus, in light of these preliminary results, we tried to detect the interaction between the E6N 
proteins in the other way around, coating the wells with GST-E6N and then incubating with 
increasing quantities of 6his-E6N. Unexpectedly, the binding curve obtained by incubating 
GST-E6N with 6his-E6N did not represent a site-specific interaction (Figure 4.11).  
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Figure 4.11. Alternative ELISA-based assay for the detection of E6N self-association. 
Microtiter plates were coated with GST-E6N and incubated with increasing amounts of 6his-
E6N. 6his-E6N bound to the coated GST-E6N was detected by the use of a HRP-conjugated 
anti-6his antibody. 
Thus, we wished to investigate a possible non-specific interaction between E6N and GST, an 
event that could possibly explain both the high association signal observed between 6his-E6N 
and GST, and the inability of 6his-E6N to compete in the presence of GST-E6N. Indeed, when 
we coated wells of microtiter plates with only GST and then incubated with 6his-E6N, we 
could detect a considerable signal of interaction. Furthermore, the association signal 
decreased following the incubation with higher amounts of 6his-E6N, suggesting a shift in the 
binding equilibrium from the interaction of E6N with GST in favour of E6N self-association 
(Figure 4.12).  
 
Figure 4.12. An ELISA-based assay demonstrates the aspecific binding of E6N to the GST 
tag. Microtiter plates were coated with GST and incubated with an equivalent amount of 
6his-E6N in the presence of increasing quantities of GST-E6N. 6his-E6N bound to the coated 
GST was detected by the use of a HRP-conjugated anti-6his antibody. 
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Thus, the observation of non-specific binding between GST and E6N protein prompted us to 
cleave the GST tag during subsequent purifications, whereas the 6his tag was maintained. 
Indeed, when we coated wells with untagged E6N, we obtained a binding curve following the 
incubation with increasing amounts of 6his-E6N, with negligible absorbances upon 
incubation with an unrelated 6his-tagged protein (6his-PA239-716; Figure 4.13). The specificity 
of the interaction was then confirmed with a competition assay, where increasing amounts 
of untagged E6N protein effectively reduced the interaction of 6his-E6N with the coated E6N. 
In contrast, addition of increasing amounts of an unrelated protein, i.e., untagged UL44 
protein from human cytomegalovirus, did not block the interaction between 6his-E6N and 
E6N, as expected (Figure 4.14), thus demonstrating that E6 can physically self-associate 
through the direct interaction between two N-terminal domains. 
 
Figure 4.13. ELISA-based 
E6N homodimerization 
assay. Microtiter plates 
were coated with 
untagged E6N and 
incubated with increasing 
amounts of 6his-E6N or 
6his-PA239-716 as a control. 
Bound proteins were 
detected by the use of a 
HRP-conjugated anti-6his 
antibody. 
 
 
Figure 4.14. An ELISA-based E6N 
competition assay confirms the 
specificity of E6N dimerization. 
Microtiter plates were coated with 
untagged E6N and incubated with an 
equivalent amount of 6his-E6N in the 
presence of increasing amounts of 
competitors untagged E6N or UL44 as 
a control. Interaction signal decreased 
only in the presence of the competitor 
E6N as expected. 
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4.1.3 The α2-helix of HPV16 E6 is important for the degradation of p53. 
 
The results presented so far demonstrate the existence of a dimeric form of HPV16 E6 in a 
cellular context. Taking into account the data published in the literature, according to which 
substitutions in the αϮ-helix of E6 were reported to significantly impair the degradation of 
p53 mediated by the viral oncoprotein [Ristriani et al., 2009], we then wished to confirm the 
importance of the hǇdƌophoďiĐ ƌesidues of the αϮ-helix of HPV16 E6 for the productive 
degradation of p53. Thus, we developed a cell-based p53 degradation assay by transfecting 
HPV-negative C33A and HEK 293T cells with plasmids encoding wild-type E6 or dimerization-
defective E6 mutants. Preliminarily, cells were subjected to test transfections by transfecting 
YFP-E6 with different transfection reagents and detecting the relative emission signals in 
order to determine the experimental conditions that allow efficient E6 overexpression (data 
not shown). HEK 293T and C33A cells were then transfected with E6, E6 F47R or E6 
F47R/Y43E and analyzed through western blotting. Indeed, while wild-type E6 triggered the 
degradation of p53, as expected, dimerization-defective E6 mutants were unable to induce 
the degradation of the endogenous p53 in both cell lines (Figure 4.15), in agreement with 
previous reports [Zanier et al., 2012]. Noteworthy, the inability of the E6 F47R and E6 
F47R/Y43E mutants to degrade p53 was observed even though these mutants had the 
propensity to accumulate at higher levels when compared to wild-type E6. This result is in 
line with previous studies reporting that the introduction of polar residues in the 
hydrophobic core of the αϮ-helix of HPV16 E6 increases the overall stability of the viral 
oncoprotein [Ristriani et al., 2009]. 
 
 
 
Figure 4.15. Cell-based p53 degradation assay. (A) C33A and (B) HEK 293T cells were 
transfected with empty vector (1) or with plasmids encoding splicing-defective E6 (2), 
splicing-defective E6 F47R (3), or splicing-defective E6 F47R/Y43E (4). Cells were harvested 
and cellular lysates were analyzed by western blotting using anti-p53, anti-HPV16 E6 (C-19), 
and anti-actin antibodies at 48 and 24 hours post-transfection for C33A and HEK 293T cells, 
respectively.
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4.1.4 The α2-helix of HPV16 E6 mediates the interaction with p53. 
 
To study whether dimerization-defective E6 mutants are unable to induce the degradation 
of p53 as a result of their inability to bind p53, rather than due to an impaired ability to self-
associate, we wished to investigate their relative capacity to bind p53 compared to the wild-
type oncoprotein. To this aim, we developed an E6-p53 BRET assay in HEK 293T cells.  
For determining the proper experimental conditions to detect the interaction between E6 
and p53 in transfected cells, we decided to use p53 as the donor RLuc-tagged partner, rather 
than the acceptor YFP-tagged protein. Indeed, using p53 as the acceptor partner would have 
resulted in the overexpression of a tumor suppressor protein in immortalized cells, with 
possible negative consequences on the proliferation and survival of transfected cells. 
Additionally, using E6 as the donor partner would have resulted in expressing low levels of 
RLuc-tagged E6 proteins. This, in turns, could have potentially resulted in the undetectable 
binding of E6 to the endogenous p53, rather than binding to the exogenous YFP-tagged p53.  
Taking into account these preliminary considerations, we chose to use p53 as the donor 
recombinant protein and E6 as the acceptor partner, and thus we constructed recombinant 
vectors expressing wild-type p53 tagged with Renilla Luciferase both at the N-terminal and 
at the C-terminal end of the tumor suppressor protein. Furthermore, according to the latest 
structural model of the E6/E6AP/p53 trimeric complex [Martinez-Zapien et al., 2016], only 
full-length E6 proteins can be used to study the interaction of E6 with p53, because both 
domains of E6, i.e., the N-terminal and C-terminal domain, are required to bind E6AP and, 
subsequently, to bind p53. HEK 293T cells were then cotransfected with either N-terminally 
or C-terminally RLuc-tagged p53 constructs in the presence of YFP-E6 4C/4S, YFP-E6 4C/4S 
F47R, YFP-E6 4C/4S F47R/Y43E or empty vector. Possible non-specific interaction was 
evaluated by cotransfecting RLuc-tagged p53 proteins with YFP-E6N, since the formation of 
the trimeric complex E6/E6AP/p53 cannot occur in the absence of the C-terminal domain of 
E6. In preliminary experiments we observed the ability of YFP-E6 4C/4S to induce the 
degradation of RLuc-tagged p53 proteins, since decreased emission signals of both RLuc-p53 
and p53-RLuc were detected when coexpressed with YFP-E6 4C/4S (data not shown). These 
data suggested that the YFP and RLuc tags did not significantly impair the ability of E6 4C/4S 
to bind, and in turn degrade, p53. Subsequent experiments were then performed 
cotransfecting USP15 and treating cells with proteasome inhibitor MG-132, in order to 
increase the expression levels of recombinant full-length E6 constructs and block the E6-
mediated degradation of p53, respectively. In this way, we could successfully detect the 
interaction between RLuc-p53 and YFP-E6 4C/4S, with an association signal of 167 ± 21 mBR, 
significantly above the background of non-specificity (Figure 4.16). Strikingly, in the same 
experimental setting, mutant recombinant constructs YFP-E6 4C/4S F47R and YFP-E6 4C/4S 
F47R/Y43E had a significantly decreased ability to bind RLuc-p53 with association signals of 
110 ± 2 mBR and 64 ± 3 mBR, respectively (Figure 4.16).  
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In addition, the same results could be obtained using the p53-RLuc construct (data not 
shown). Thus, these results suggest that the introduction of the same point mutations that 
disrupt E6 homodimerization are also impairing the binding between E6 and p53, in 
agreement with the recently published results [Martinez-Zapien et al., 2016].  
 
Figure 4.16. BRET assay monitoring the interaction between p53 and wild-type or mutant 
E6 proteins. HEK 293T cells were transfected with RLuc-p53 in the presence of YFP-E6 4C/4S, 
YFP-E6 4C/4S F47R or YFP-E6 4C/4S F47R/Y43E. Mutant E6 4C/4S proteins showed a 
significant reduced ability to bind p53 when compared to wild-type E6. Control of non-
specificity was obtained by cotransfecting HEK 293T cells with RLuc-p53 and YFP-E6N. 
 
 
4.1.5 HPV16 E6 homodimerization and E6-p53 interaction are two 
independent processes. 
 
The results presented so far demonstrate that the homodimerization of HPV16 E6 and the 
binding of HPV16 E6 to p53 are two protein-protein interactions (PPIs) that involve the same 
key residues of the hǇdƌophoďiĐ Đoƌe of the α2-helix. Accordingly, these PPIs appear to be 
likely two distinct processes occurring on the same surface of the viral oncoprotein.  
Thus, to test whether indeed p53 can bind E6 independently of the homodimerization of the 
viral oncoprotein, we sought to investigate whether these interacting partners could 
compete with each other for the binding on the same interaction surface on E6. To this aim, 
we developed a BRET competition assay in HEK 293T cells.   
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In theory, the physical competition between p53 and E6 could be studied by detecting E6-
p53 interaction in the absence or presence of a competitor E6, or vice versa, by detecting the 
homodimerization of E6 in the absence or presence of p53. However, considering the low 
steady-state levels of E6 in transfected cells, we chose to perform the BRET competition 
assay through the second strategy, wherein the self-association of E6 is detected in the 
presence of the competitor p53. This is justified also by the impossibility to express high 
levels of E6 through transient transfection techniques, particularly when employing an 
untagged protein. In addition, the use of small tags or untagged competitors should be 
preferred in competition assays, since the steric hindrance induced by the addition of large 
tags could possibly prevent an efficient competition.   
Thus, HEK 293T cells were cotransfected with RLuc-E6 4C/4S and YFP-E6 4C/4S in the 
absence or the presence of exogenous HA-tagged p53. As previously described, transfections 
were performed in the presence of USP15 and cells were treated with proteasome inhibitor 
MG-132 prior to data collection. Although this experimental setting was originally required 
to enhance the expression levels of recombinant full-length E6 proteins, treatment with 
proteasome inhibitor MG-132 in the presence of USP15 also results in the downregulation of 
the E6-mediated degradation of p53, an event that could have induced the degradation of 
the competitor. As a positive control, RLuc-E6 4C/4S and YFP-E6 4C/4S were cotransfected 
with FLAG-E6N in the same experimental conditions. Strikingly, in repeated experiments we 
never observed the ability of exogenous p53 to compete with E6 self-association, nor to 
stabilize the formation of the dimeric form of E6, while FLAG-E6N successfully impaired the 
binding of YFP-E6 4C/4S to RLuc-E6 4C/4S (Figure 4.17). Taken together, these results 
indicate that E6-p53 interaction and E6 homodimerization are likely two separated processes 
which occur independently of each other, as suggested by the inability of p53 to compete 
with E6 self-association. 
Figure 4.17. BRET competition assay in HEK 293T 
cells shows the inability of exogenous p53 to 
compete with E6 self-association. HEK 293T cells 
were transfected with recombinant E6 4C/4S 
proteins in the absence or the presence of 
competitor proteins HA-p53 and E6AP. As a 
positive control, RLuc- and YFP- tagged E6 4C/4S 
constructs were cotransfected with FLAG-E6N. 
Cells were then harvested and cellular lysates 
were analyzed by western blotting using anti-p53, 
anti-FLAG, and anti-actin antibodies. 
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4.1.6 Effects of HPV16 E6 on Scribble protein levels. 
 
The previous observation that the homodimerization of E6 occurs independently of the 
binding of E6 to p53 disagrees with the original model in which E6 self-association was 
proposed as a necessary step for the degradation of p53 [Zanier et al., 2012]. However, our 
results strongly agree with the structural model of the E6/E6AP/p53 trimeric complex and 
support the idea that E6 homodimerization is an independent process that likely is not 
involved in the degradation of p53 [Martinez-Zapien et al., 2016].   
Thus, in an attempt to determine the role of the dimeric form of E6 in the context of its 
transforming activities, we sought to investigate the possible correlation between E6 self-
association and the degradation of other proteins known to be targeted by the viral 
oncoprotein, for example, the cytoplasmic PDZ-containing cellular proteins.   
Particularly, we studied the effect of wild-type E6 and dimerization defective mutants on the 
levels of the PDZ-containing protein Scribble, which is known to be a favourite target of 
HPV16 E6 [Thomas et al., 2016]. Thus, we transfected HPV-negative C33A and HEK 293T cells 
with either wild-type E6 or dimerization-defective E6 mutants, and analyzed the endogenous 
levels of Scribble by western blotting. We chose to use both C33A and HEK 293T cells 
because of their different cellular morphology. Although both are epithelial cell lines, round-
shaped C33A cells might possess altered or mislocalized levels of Scribble due to the known 
tendency of malignant cells to loose focal adhesions and adherence in general. On the 
contrary, HEK 293T cells still retain an epithelial-like morphology characterized by distinctive 
membrane protrusions, ECM-cell and cell-cell junctions that correlate with the proper 
expression and localization of Scribble and cytoskeletal proteins in general.   
Unfortunately, we failed to find a correlation between E6 homodimerization and the E6-
mediated degradation of Scribble in both cell lines, since no difference in the levels of 
Scribble was detected upon overexpression of dimerization-defective E6 mutants (F47R and 
F47R/Y43E) as compared to the wild-type E6 protein (Figure 4.18). However, Scribble 
degradation was not observed even in cells transfected with wild-type E6, a result that 
contrasts with previous studies reporting the E6-mediated degradation of Scribble and other 
cellular PDZ-containing proteins [Nakagawa and Huibregtse, 2000; Massimi et al., 2004]. A 
possible explanation for these discrepancies is disĐussed iŶ the ͞DisĐussioŶ aŶd CoŶĐlusioŶs͟ 
chapter.  
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Figure 4.18. Effect of wild-type E6 or dimerization-defective E6 mutants on the 
endogenous levels of Scribble. (A) C33A and (B) HEK 293T cells were transfected with empty 
vector (1) or with plasmids encoding splicing-defective E6 (2), splicing-defective E6 F47R (3), 
or splicing-defective E6 F47R/Y43E (4). Cells were harvested and cellular lysates were 
analyzed by western blotting using anti-Scribble, anti-HPV16 E6 (C-19), and anti-actin 
antibodies at 48 and 24 hours post-transfection for C33A and HEK 293T cells, respectively. 
 
 
4.1.7. The dimerization of HPV16 E6 is required for the upregulation of TAZ. 
 
Recently, the interplay between the activity of high-risk E6 proteins and Hippo signaling 
pathway has been reported [He et al., 2015]. In fact, it was shown that high-risk E6 
oncoproteins are capable of upregulating YAP as a result of the E6-mediated degradation of 
SOCS6, a known YAP inhibitor. Thus, we sought to investigate whether E6 self-association 
might correlate with YAP, and/or possibly TAZ, upregulation, the two main transducers of 
the Hippo signaling cascade.   
Preliminarily, we wished to confirm the E6-mediated upregulation of YAP in our 
experimental setting, and thus C33A cells were transfected with wild-type E6 or 
dimerization-defective E6 mutants and transfected cells were harvested at high density for 
western blot analysis. Strikingly, in an attempt to detect the accumulation of the 
endogenous levels of YAP following the expression of wild-type or mutant E6 proteins, we 
observed that wild-type HPV16 E6 was able to upregulate TAZ and, most importantly, this 
effect was abolished by the introduction of polar residues in the hydrophoďiĐ Đoƌe of the αϮ-
helix (Figure 4.19). However, dimerization-defective mutants that were not able to 
upregulate TAZ were still able to upregulate YAP, suggesting the possible involvement of E6 
self-association only in the stabilization of TAZ, rather than YAP, protein levels (data not 
shown).  
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Figure 4.19. Effect of wild-type E6 or 
dimerization-defective E6 mutants on the 
endogenous levels of TAZ. C33A cells were 
transfected with empty vector (1) or with 
plasmids encoding splicing-defective E6 (2), 
splicing-defective E6 F47R (3), or splicing-
defective E6 F47R/Y43E (4). Cells were grown 
in serum-reduced conditions (1% FBS), 
harvested at high density and cellular lysates 
were analyzed by western blotting using anti-
TAZ, anti-HPV16 E6 (C-19), and anti-actin 
antibodies at 48 hours post-transfection. 
 
Indeed, in repeated experiments we confirmed that TAZ upregulation possibly depends on 
the self-association of E6, since dimerization-defective E6 mutants were constantly 
incapable of stabilizing TAZ in transfected cells (Figure 4.20A). Nevertheless, we wished to 
further support the idea that the homodimerization of E6 might be a key interaction 
necessary for the upregulation of TAZ. To this aim, we wanted to study TAZ upregulation 
mediated by E6 in the absence of p53, in order to exclude the involvement of the interaction 
between E6 and p53, which occurs through the same protein surface on the viral 
oncoprotein. Thus, we transfected H1299 cells, a p53-null epithelial cancer cell line, with the 
same constructs and analyzed the endogenous levels of TAZ by western blotting when the 
cells reached confluence. Strikingly, we observed the upregulation of TAZ only upon 
overexpression of wild-type E6 also in this cell line (Figure 4.20B), in agreement with the 
previous result obtained in C33A cells. 
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Figure 4.20. E6 homodimerization-dependent upregulation of TAZ. (A) C33A and (B) H1299 
cells were transfected with plasmids encoding splicing-defective E6 (1), splicing-defective E6 
F47R (2), or splicing-defective E6 F47R/Y43E (3). Cells were grown in serum-reduced 
conditions (1% FBS), harvested at high density and cellular lysates were analyzed by western 
blotting using anti-TAZ, anti-HPV16 E6 (C-19), and anti-actin antibodies at 48 and 24 hours 
post-transfection for C33A and H1299 cells, respectively. 
 
 
4.2 Studies on the development of anti-E6 compounds targeting the α2-helix 
of HPV16 E6. 
 
4.2.1 In silico screenings. 
 
In parallel to the biological studies investigating the role of the dimeric form of E6 in the 
context of the E6-mediated mechanisms of cellular transformation, we performed, in 
collaboration with the group of prof. Gabriele Cruciani (University of Perugia, Italy), in silico 
drug screenings in order to search for small ŵoleĐules aďle to taƌget the αϮ-helix of HPV16 
E6. 
The first in silico screening was aimed at identifying compounds able to impair E6 self-
association. The N-terminal domain of E6 from the NMR dimer structure (pdb: 2LJY) was 
used as a template [Zanier et al., 2012]. The screening was conducted against a druggable 
pseudo-cavity that we identified around Phe47 of E6 and the Specs database was screened 
with FLAP (Fingerprints for Ligands And Proteins) software [Baroni et al., 2007]. A prefiltering 
run was performed, fixing the interaction with Phe47 of the chain A of the dimer structure as 
a constraint. Prefiltering results were ranked by the GlobSum descriptor, and the 100 top-
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ranked compounds were used to generate a GRID Molecular Interaction Fields (MIFs)-based 
database in FLAP. Thus, the screening was refined according to the calculated MIFs and the 
results were ranked by GlobProd descriptor in order to obtain a ranking of potentially active 
compounds (data not shown).   
Subsequently, a second in silico screening was performed taking advantage of the crystal 
structure of the trimeric complex E6/E6AP/p53, and using the chain of E6 as the target 
structure. The strategy was the same as described before but the screening was performed 
also against two larger virtual databases, i.e., the ChemDiv and Vitas-M databases. 
Noteworthy, the druggable cavity identified with this screening partly but significantly 
overlapped the pseudo-cavity previously identified using the NMR dimeric structure of 
HPV16 E6 (Figure 4.21). Indeed, E6 self-association and the interaction of E6 with p53 
involve the same key residues in the hydrophobic core of the αϮ-helix.  
Fourteen compounds, among the 50 top-ranked which resulted positive hits in both 
screenings, were then selected for testing, based on chemical diversity and availability 
criteria. 
 
 
 
Figure 4.21. Druggable pockets at the E6/E6AP-p53 and E6 dimerization binding interfaces. 
(A) Druggable cavity at the E6/E6AP-p53 binding interface calculated on the E6/E6AP/p53 
crystal structure (PDB accession code: 4XR8); (B) Druggable cavity at the E6 dimerization 
interface calculated on the NMR E6 dimeric structure (PDB accession code: 2LJY); (C) Overlap 
between the two detected cavities. For clarity, virtual cavities were superimposed on the 
model of full-length HPV16 E6 of the E6/E6AP/p53 crystal structure. 
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4.2.2 Ability of the compounds to impair HPV16 E6 self-association. 
 
To test the ability of selected compounds to inhibit E6 self-association, we used the ELISA-
based E6N homodimerization assay to perform a dose-response analysis of the 14 hit 
compounds. Dose-response analyses of the inhibition of E6 dimerization were performed by 
assaying four concentrations (10-50-100-200 μM) of each compound and IC50 values 
(compound concentration that reduces E6N dimerization by 50%) were estimated. Among 
the hits, two compounds – 6 and 12 – exhibited the strongest inhibitory activity (IC50 values 
of 40 ± 12 and 20 ± 5 µM, respectively). Two other compounds – 11 and 14 – caused a 
reproducible dose-dependent reduction, but with higher IC50 values. The remaining 
compounds did not exhibit any inhibitory activity at the tested concentrations (data not 
shown). Importantly, an unrelated small molecule, FLU-1, previously shown to inhibit the 
influenza A virus PA-PB1 interaction [Muratore et al., 2012], did not interfere with E6N 
dimerization (Figure 4.22). 
 
 
Figure 4.22. Inhibitory activity of test compounds in ELISA E6N homodimerization assays. 
Inhibition curves obtained for some of the hits selected in the in silico screening (compounds 
3, 6, 11, 12, and 14), and of an unrelated protein-protein interaction inhibitor (FLU-1) as a 
control. Data shown represent the mean ± SD of at least two independent experiments. 
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4.2.3 Effects of the compounds on the viability of HPV-positive cells. 
 
In parallel to the investigation of the in vitro activity of the selected small molecules, 
compounds cytotoxicity was measured by the MTT assay in several cell lines. Compounds 
were tested both on HPV-positive (Hela, SiHa, CaSki) and on HPV-negative (C33A) cervical 
cancer cells, and non-tumoral human cells (e.g. HFF) as controls, in order to determine the 
specific and non-specific cytotoxicity of each compound, respectively. Preliminarily, cell 
growth curves were obtained in order to determine the proper number of cells to be plated 
for compound testing (data not shown) and then CC50 values (compound concentration that 
causes a decrease of cell viability by 50%) were estimated. All the compounds that were 
inactive in vitro did not exhibit significant cytotoxic effect on HPV-positive cells, and those 
that exhibited mild cytotoxicity on Hela, SiHa and CaSki cells (such as compound 11) were 
also mildly cytotoxic for C33A and HFF cells (data not shown). However, compound 6 and 12 
exhibited toxic effects preferentially on HPV-positive cells, with overall minor cytotoxicities 
on the HPV-negative cell lines tested (Figure 4.23), suggesting their ability to induce cell 
death in HPV-positive cells as a result of specific anti-E6 activity. In parallel, compound 3 was 
inactive as expected. 
 
Figure 4.23. Cytotoxic effect of test compounds on the viability of HPV-positive cells. 
Cytotoxic effects obtained for some of the compounds selected in the in silico screening 
(compounds 3, 6, and 12) on the viability of Hela (HPV18-positive), SiHa (HPV16-positive), 
CaSki (HPV16-positive), C33A (HPV-negative) cervical carcinoma cells and on HFF (human 
foreskin fibroblast) cell line. Cytotoxicities were assessed by the MTT assay after 48 hours of 
treatment and compared to that of non-treated cells. 
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4.2.4 Compound 12 impairs the HPV16 E6-mediated degradation of p53 and 
enhances the downregulation of HPV16 E6.  
 
The results presented so far suggest that two compounds – 6 and 12 – are capable of 
disrupting the dimerization HPV16 E6 and might potentially act against the activity of the 
endogenous E6 proteins expressed in HPV-positive Hela, SiHa, and CaSki cells. Thus, we 
sought to investigate the ability of these compounds to impair the binding between E6 and 
p53. However, we were not able to test these compounds in an in vitro E6-p53 binding assay 
mainly due to the difficulty in purifying wild-type full-length HPV16 E6, since the full-length 
protein is required to mediate the interaction with p53. Thus, we studied the ability of these 
two compounds to inhibit the E6-dependent degradation of p53 in transfected cells. To this 
aim, we transfected C33A cells with a plasmid encoding full-length untagged HPV16 E6 and 
then we treated the transfected cells with compounds 6, 12 and 3 (the latter used as a 
negative control) each at two different concentrations below their respective CC50 values 
and analyzed the endogenous levels of p53, as well as the expression of E6, by western 
blotting. Noteworthy, compound 12, unlike compound 6, was able to rescue p53 in 
transfected cells, suggesting its ability to impair the interaction between E6 and p53, which 
results in the inhibition of p53 degradation, while compound 3 was inactive as expected 
(Figure 4.24A). Furthermore, in repeated experiments we observed the downregulation of 
E6 protein levels following treatment with compound 12, which suggested the possible 
ability of this compound to induce the degradation of E6, since the levels of the internal 
control, i.e. actin, were not affected (Figure 4.24B).  
 
 
Figure 4.24. Activity of compounds 6 and 12 on the levels of p53 and E6. (A and B) C33A 
cells were transfected with empty vector (1) or with plasmid encoding splicing-defective 
HPV16 E6 (2 to 8). Cells were treated with DMSO (NT) or with compounds 3 (not shown in B) 
and 6 at 50 μM and 100 μM and with compound 12 at 20 μM and 50 μM. Cells were 
harvested and cellular lysates were analyzed by western blotting using anti-p53, anti-HPV16 
E6 (N-17), and anti-actin antibodies at 48 hours post-transfection. 
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Thus, to test whether this compound could enhance the proteasome-dependent turnover of 
E6, we treated C33A cells, transfected with wild-type E6, with compound 12 in the absence 
or presence of proteasome inhibitor MG-132. Strikingly, we observed that E6 protein levels 
were rescued in cells treated with MG-132, thus suggesting the ability of compound 12 to 
enhance E6 degradation through the cellular proteasome machinery (Figure 4.25). Finally, to 
test whether compound 12 may have induced the downregulation of E6 as a result of its 
direct binding to the viral oncoprotein, rather than through an indirect mechanism, we 
transfected C33A cells with full-length wild-type E6 or mutant E6 F47R and cells were treated 
with compound 12. Notably, we observed that E6 downregulation was higher in cells 
transfected with wild-type E6 rather than in cells transfected with mutant E6 F47R, 
suggesting an impaired binding affinity between E6 F47R and compound 12 (Figure 4.26). 
 
 
Figure 4.25. Proteasome-dependent 
downregulation of E6 protein levels 
induced by compound 12. C33A cells were 
transfected with empty vector (1) or with 
plasmid encoding splicing-defective HPV16 
E6 (2 to 5). Cells were treated with DMSO 
or with compound 12 at 20 μM (+) and 50 
μM (++) in the absence or the presence of 
proteasome inhibitor MG-132 (40 μM). 
Cells were harvested and cellular lysates 
were analyzed by western blotting using 
anti-p53, anti-HPV16 E6 (N-17), and anti-
actin antibodies at 48 hours post-
transfection. 
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Figure 4.26. Differential affinity of compound 12 towards wild-type E6 and mutant E6 
F47R. (A) C33A cells were transfected with empty vector (1 and 4) or with plasmid encoding 
splicing-defective HPV16 E6 (2 and 3) or splicing-defective HPV16 E6 F47R (5 and 6). Cells 
were treated with DMSO or with compound 12 at 50 μM. Cells were harvested and cellular 
lysates were analyzed by western blotting using anti-p53, anti-HPV16 E6 (N-17 for wild-type 
E6; C-19 for E6 F47R), and anti-actin antibodies at 48 hours post-transfection. (B) 
Quantification of E6 protein bands detected in (A) by western blot analysis. Bands were 
quantified using ImageJ Software (NIH, USA). 
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4.2.5 Effects of active compounds on the proliferation of HPV-positive cells. 
 
Finally, we wanted to study the effects of these two compounds also against the 
proliferative capacity of HPV-positive cells. Thus, we performed both 2D clonogenic assays 
on plastic and 3D clonogenic assays on soft agar matrix, in order to determine the 
proliferation of cells after treatment with compounds 3, 6 and 12. For 2D colony formation 
assays, Hela, SiHa, CaSki and C33A cells, the last included as a control to verify whether the 
effects of the compounds are specific for E6-expressing cells, were plated and treated with 
the compounds for 2 weeks. Notably, compounds 6 and 12, but not compound 3, drastically 
reduced the number and size of colonies of Hela, SiHa and CaSki cells, while having no or 
minor effects on the proliferation of C33A cells at the tested concentrations of 100 and 50 
μM, respectively (Figure 4.27).  
 
Figure 4.27. Anti-clonogenic properties of test compounds. 2D colony formation assay was 
used to evaluate the long-term (14 days) effects of compounds 3, 6, and 12 on Hea, CaSki, 
SiHa HPV-positive cervical carcinoma cell lines, compared to non-treated cells (DMSO). HPV-
negative cervical carcinoma C33A cells were used as a negative control to test the specificity 
of compounds in targeting E6. Silencing of E6/E7 (E6/E7 siRNA) in HPV-positive cervical 
carcinoma cell lines, compared with scrambled siRNA (CTR siRNA), was used as a positive 
control (right panel). 
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Additionally, the inhibition of proliferation capacity of compound-6 and -12-treated cells was 
close to that of the positive control wherein the expression of E6 and E7 was downregulated 
through the use of anti-E6/E7 siRNAs, which were shown to successfully induce senescence 
and apoptosis due to the restoration of p53 levels [Koivusalo et al., 2005]. Finally, we studied 
the ability of these compounds to impair the anchorage-independent growth of HPV-positive 
cells in soft agar colony formation assays. Noteworthy, similar results were obtained, 
wherein the anchorage-independent proliferation of Hela, SiHa and CaSki cells was 
significantly reduced upon treatment with compounds 6 and 12 for up to 8 weeks, while 
compound 3 exhibited almost no effect (Figure 4.28). Unfortunately, we could not include 
C33A cells in these assays for their inability to grow on soft agar matrices [Villanueva-Toledo 
et al., 2014]. 
 
Figure 4.28. Anti-clonogenic 
properties of test compounds 
in anchorage-independent 
growth assays. Soft agar colony 
formation assay was used to 
evaluated the long-term (up to 2 
months) effects of compounds 
3, 6, and 12 on (A) Hela, (B) 
CaSki and (C) SiHa HPV-positive 
cell lines. Cells treated with 
DMSO were used as a negative 
control. Silencing of E6/E7 
(E6/E7 siRNA), compared with 
scrambled siRNA (CTR siRNA), 
was used as a positive control 
(right bars). 
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5. Discussion and Conclusions 
 
By the use of a cell-based technique for the detection of protein-protein interactions, i.e., 
Bioluminescence Resonance Energy Transfer (BRET), we studied and characterized the self-
association of full-length HPV16 E6 in living cells. BRET turned out to be a potent qualitative 
and quantitative technique to detect protein-protein interactions in living cells. Taking 
advantage of the high expression levels that can be achieved by the use of HEK 293T cell line, 
we successfully detected the homodimerization of the N-terminal domain of E6 and a full-
length E6 isoform, named E6 4C/4S, where four non-conserved cysteines on protein surface 
are mutated into serines, preventing E6 protein aggregation in vitro, albeit not impairing E6 
degradative functions [Zanier et al., 2010; Zanier et al., 2012]. The use of a non-aggregating 
isoform was required, as the overexpression of YFP-tagged wild-type E6 induced the 
formation of nuclear foci, recently characterized as nuclear aggresomes, which are 
distinctive perinuclear compartments induced by the accumulation of misfolded and 
aggregated proteins [Stutz et al., 2015]. An intrinsic limit of the BRET technique is the 
overexpression of the acceptor partner (i.e. the YFP-tagged protein) in order to saturate the 
donor partner (i.e. the RLuc-tagged protein), especially when dealing with putative weak 
protein-protein interactions, as higher levels of the recombinant acceptor protein is 
required. Indeed, E6 homodimerization was previously shown to be a weak interaction, at 
least in vitro [Zanier et al., 2012]. Thus, we speculate that the inability to detect wild-type E6 
homodimerization by this assay is justified by the E6-induced aggresome formation which 
ideally caused a loss of active, properly folded E6 molecules, hence decreasing the 
detectable signal of interaction. Nevertheless, the use of the non-aggregating isoform E6 
4C/4S successfully prevented recombinant protein aggregation in transfected cells and 
resulted in a detectable interaction. Notably, the self-association signal detected for E6 
4C/4S was close to the signal detected using E6N recombinant proteins at similar Y/R values, 
suggesting a homodimerization of E6 driven specifically by the N-terminal domain of the 
protein, as previously reported [Zanier et al., 2012]. Most importantly, the introduction of 
one or two substitutions in the dimeric interface, that were previously reported to block the 
homodimerization in vitro (F47R and F47R/Y43E), effectively reduced the interaction also in 
transfected cells, thus confirming the specificity of the observed interaction signal. 
Furthermore, the quantitative analysis of E6N, E6N F47R, and E6N F47R/Y43E self-
associations, performed by a BRET saturation assay in HEK 293T cells, revealed that the 
substitution of residue 47 is sufficient to inhibit the interaction almost completely, as the 
binding curves of E6N F47R and E6N F47R/Y43E mostly overlap and are very close to the non-
specific background.  
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The detection of E6N self-association in an in vitro ELISA-based assay further supported the 
occurrence of the homodimerization as a result of a direct self-interaction, ruling out the 
possibility of a bridging effect, where other cellular binding partners may have induced the 
close contact of two E6 molecules in our BRET experiments. In addition, the ELISA-based in 
vitro assay confirmed the occurring self-association of the N-terminal domains of E6 with 
high specificity and overall good sensitivity. Taken together, these results demonstrate the 
effective existence of a dimeric form of E6 in a cellular context, and although we were 
unable to calculate the dissociation constant (Kd), they point to a weak interaction, as 
previously reported [Zanier et al., 2012]. This can be inferred, on the one hand, by the high 
expression levels of YFP-E6N required to saturate the RLuc-E6N protein in the BRET saturation 
assay (i.e. the very high Y/R values at which the E6N binding curve reaches the plateau) and, 
on the other hand, by the high amount of purified protein required to saturate the binding 
partner in the ELISA assay. 
The importance of the hydrophobic residues of α2-helix with regard to E6 transforming 
activities was correlated to the ability of the viral oncoprotein to successfully degrade p53, 
and indeed, we confirmed the importance of this hydrophobic surface for the productive 
degradation of p53 in transfected cells. However, contrasting results were published about 
the ability of mutant E6 F47R to bind p53, and thus, whether the dimerization was really an 
event necessary for the degradation of p53 remained an open question. To this aim, we 
studied the interaction between E6 and p53 in living cells and, remarkably, mutant E6 F47R 
and E6 F47R/Y43E had binding capacities significantly reduced compared to wild-type E6 and 
thus, our data appear to be in keeping with the latest structural model of the E6/E6AP/p53 
trimeric complex and explain the inability to degrade p53 as a result of an impaired binding 
capacity [Martinez-Zapien et al., 2016].  
In line with these results, we then tested whether E6 self-association and the binding of E6 
to p53 could compete with each other as a result of two distinct interactions occurring on 
the same surface on the viral oncoprotein. Notably, in repeated experiments, we never 
observed a reduction of E6 self-association in the presence of exogenous p53, whereas 
FLAG-E6N could successfully impair the interaction between RLuc-E6 4C/4S and YFP-E6 4C/4S 
in the same experimental conditions. Thus, taken together, our results point to the exclusion 
of E6 self-association from being a protein-protein interaction required to form the protein 
complex which induces the degradation of p53, and suggest the involvement of E6 self-
association in other molecular processes. In addition, the occurrence of these two 
interactions likely take place in different cellular compartments, as suggested by the inability 
of p53 to compete with E6 homodimerization. Indeed, p53 is a well known nuclear protein 
whose intracellular localization is due to the presence of different sequences important for 
its nuclear import [Liang and Clarke, 1999]. Furthermore, the N-terminal domain of E6, 
which was able to compete with E6 self-association in our BRET competition assay, localizes 
both in the nucleus and the cytoplasm of transfected cells. Thus, we speculate that the 
cytoplasmic fraction of FLAG-E6N was likely responsible for the impairment of E6 
homodimerization. Although further experiments are required to study the intracellular 
localization of E6 dimers, oligomeric forms of E6 were already reported to localize in the 
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cytosol of HPV-positive cells and to target cytoplasmic cellular proteins [Garcia-Alai et al., 
2007(b)]. Thus, we propose a model in which nuclear E6 binds to p53 as a monomer, while 
cytoplasmic E6 can dimerize and interact with other cellular targets. 
In order to investigate the possible role of E6 homodimerization, and in line with our 
aforementioned observations, we monitored the endogenous levels of another known 
cellular target of E6, the cytoplasmic PDZ-containing protein Scribble, following the 
expression of E6 in HPV-negative cell lines. Unfortunately, we failed to find a correlation 
between the homodimerization of the viral oncoprotein and Scribble degradation following 
western blot analysis of cells transfected with either wild-type E6 or dimerization defective 
mutants. However, we did not observe a loss of Scribble even in cells transfected with wild-
type E6, a result that contrasts with previous studies reporting the E6-induced E6AP-
dependent degradation of Scribble [Nakagawa and Huibregtse, 2000]. Nevertheless, some 
studies previously reported the E6-mediated delocalization of Scribble rather than its 
degradation [Choi et al., 2014], and thus our results appear to be in line with these more 
recent observations.  
The recent discovery of the crosstalk between the Hippo transducer YAP and E6 in HPV-
positive cancer cells prompted us to test whether E6 dimerization could be related to YAP 
upregulation [He et al., 2015]. Strikingly, in an attempt to monitor the endogenous levels of 
YAP in cells transfected with wild-type E6 or dimerization-defective E6 mutants, we observed 
that E6 mediates also the upregulation of TAZ, the other main transducer of the Hippo 
signaling cascade. Most importantly, we observed the inability of dimerization-defective E6 
mutants to upregulate TAZ in the same experimental conditions, and the same result could 
be observed also in H1299 cells, a p53-null cell line. This, in turns, suggests that the 
hydrophobic core of the α2-helix of HPV16 E6 is crucial for TAZ upregulation and the 
mechanism does not depend on the interaction between E6 and p53, but involves another 
protein-protein interaction occurring on the same protein surface. We propose E6 self-
association as the candidate interaction required for the upregulation of TAZ. Furthermore, 
Scribble is known to be a cytoplasmic scaffold protein which serves as a TAZ inhibitor and its 
delocalization has been already reported to induce TAZ accumulation in the nucleus 
[Cordenonsi et al., 2011]. Thus, in line with our previous considerations, it may be worth 
investigating whether the cytoplasmic dimeric form of E6 induces Scribble delocalization 
which in turns results in the upregulation of TAZ. Indeed, further research will be conducted 
with the goal to investigate the precise molecular mechanisms behind this process.  
 
The identification of a druggable pseudo-cavity around Phe47 allowed us to select several 
potential inhibitory small molecules by an in silico screening aimed at serching E6 
dimerization inhibitors. Not surprisingly, the second in silico screening, performed against a 
pseudo-cavity at the E6-p53 binding sub-interface II, clearly showed the significant overlap 
between the two cavities. This observation resulted in the possibility to develop dual 
inhibitors able to disrupt simultaneously both E6 self-association and E6-p53 interaction.  
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Initially, we tested the inhibitory activity of the 14 selected compounds that resulted positive 
hits in both screenings in the ELISA E6N homodimerization assay, and we could identify two 
compounds, 6 and 12, that successfully inhibited E6 homodimerization with an IC50 of ~40 
μM and ~20 μM, respectively. Furthermore, both compounds showed to be specifically 
cytotoxic for HPV-positive cell lines, although compound 6 showed a CC50 four times higher 
than its IC50 observed in vitro.  
Starting from these initial observations, we tested the ability of compounds 6 and 12 to 
impair the E6-mediated degradation of p53 in cells transfected with wild-type full-length 
HPV16 E6. Noteworthy, compound 12, but not compound 6, was able to rescue p53 levels in 
transfected cells, suggesting the inhibition of E6-p53 interaction induced by compound 12. 
Additionally, in repeated experiments we also observed the ability of compound 12 to 
induce the downregulation of E6 protein levels in transfected cells, in a dose-dependent 
manner. Indeed, E6 is known to be degraded by the proteasome machinery within infected 
cells [Stewart et al., 2004], and thus we investigated whether compound 12 could induce E6 
degradation in a proteasome-dependent manner. Strikingly, cells treated with compound 12 
in the presence of the proteasome inhibitor MG-132 showed higher E6 levels compared to 
those of transfected cells treated only with compound 12.   
Finally, to test whether compound 12 is enhancing E6 clearance as a result of a possible 
direct interaction with the viral oncoprotein, cells were transfected either with wild-type E6 
or dimerization-defective E6 F47R. Noteworthy, compound 12 showed a reduced capacity to 
downregulate the levels of E6 F47R compared to wild-type E6 in the same experimental 
conditions. Thus, these preliminary data suggest that compound 12 is counteracting E6 by 
directly binding to the viral oncoprotein, preventing the interaction and degradation of p53 
and enhancing E6 degradation through the cellular proteasome machinery. 
Furthermore, these results agree with the data from the MTT assays in which compound 12 
was shown to be preferentially cytotoxic for HPV-positive cells. Noteworthy, also compound 
6 resulted to be toxic for HPV-positive cells in the MTT assays, although this compound could 
not rescue p53 levels in E6-transfected cells. Thus, we wished to test the anti-proliferative 
activity of both compounds, 6 and 12, in 2D and 3D clonogenic assays. Surprisingly, both 
compound 12 and compound 6 showed anti-proliferative activity in HPV-positive cells, while 
producing no or minimal effect against HPV-negative cell lines. This observation further 
supports the idea that E6 homodimerization has a role in the oncogenic functions of E6 and 
heralds the prospect of developing dual inhibitors that, by interfering with both the PPIs 
driven by the α2-helix of the N-terminal domain of E6, could block multiple activities of the 
viral oncoprotein important for its transforming activities. This, on the one hand, can be 
explained by the anti-proliferative activity of compound 6 that we identified as an inhibitor 
of E6 dimerization while appearing unable to block the E6-mediated p53 degradation, and, 
on the other hand, by the ability of compound 12 to impair both E6 self-association and the 
E6-mediated degradation of p53, thus possibly representing a candidate dual inhibitor. In 
the future, further research will be carried out to study the anti-proliferative activity of 
compound 6 with regard to the oncogenic function of E6 homodimerization. 
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